Document:

Exhibit
10.1B+

 

VBI
Vaccines INC.

 

Incentive
PLAN

 

Effective
May 6, 2016

 

As
amended December 16, 2021

 

    	 

    	 

    

 

PART
I – GENERAL PROVISIONS

 

	1.	PREAMBLE
                                            AND DEFINITIONS

 

	 	1.1	Title.

 

The
Plan described in this document shall be called the “VBI Vaccines Inc. Incentive Plan”

 

	 	1.2	Purpose
    of the Plan.

 

The
purposes of the Plan are:

 

	 	(a)	to
    promote a further alignment of interests between officers, employees and other eligible service providers and the shareholders of
    the Corporation;
	 	 	 
	 	(b)	to
    associate a portion of the compensation payable to officers, employees and other eligible service providers with the returns achieved
    by shareholders of the Corporation; and
	 	 	 
	 	(c)	to
    attract and retain officers, employees and other eligible service providers with the knowledge, experience and expertise required
    by the Corporation.

 

	 	1.3	Definitions.

 

	 	1.3.1	“Affiliate(s)”
    shall mean a Parent or Subsidiary of the Corporation.
	 	 	 
	 	1.3.2	“Applicable
    Law” means any applicable provision of law, domestic or foreign, including, without limitation, applicable securities legislation,
    together with all regulations, rules, policy statements, rulings, notices, orders or other instruments promulgated thereunder, and
    Stock Exchange Rules.
	 	 	 
	 	1.3.3	“Base
    Price” means the base dollar amount used to calculate the amount, if any, payable to a Participant with respect to a Share
    subject to a Stand-Alone SAR upon settlement thereof, which base dollar amount shall be determined in accordance with Section 10.6.
	 	 	 
	 	1.3.4	“Beneficiary”
    means, subject to Applicable Law, an individual who has been designated by a Participant, in such form and manner as the Board may
    determine, to receive benefits payable under the Plan upon the death of the Participant, or, where no such designation is validly
    in effect at the time of death, the Participant’s legal representative.
	 	 	 
	 	1.3.5	“Black-Out
    Period” means a period of time when, pursuant to any policies of the Corporation, any securities of the Corporation may
    not be traded by certain persons as designated by the Corporation, including any holder of a Grant.
	 	 	 
	 	1.3.6	“Board”
    means the Board of Directors of the Corporation.

 

    	1

    	 

    

 

	 	1.3.7	“Cause”
    means:

 

	 	(a)	subject
    to (b) below, “just cause” or “cause” for Termination by the Corporation or an Affiliate as determined under
    Applicable Law;
	 	 	 
	 	(b)	where
    a Participant has a written employment agreement with the Corporation or an Affiliate, “Cause” as defined in such
    employment agreement, if applicable; or
	 	 	 
	 	(c)	where
    a Participant provides services as an independent contractor pursuant to a contract for services with the Corporation or an Affiliate,
    any material breach of such contract.

 

	 	1.3.8	“Change
    in Control” means:

 

	 	(a)	a
    successful “take-over bid” (as defined in the Securities Act (British Columbia), as amended, or any successor
    legislation thereto) pursuant to which the “offeror” acquires beneficial ownership of securities of the Corporation which,
    directly or following conversion or exercise thereof, would entitle the holder thereof, together with persons acting jointly or in
    concert with the holder thereof, to cast more than fifty percent (50%) of the votes attaching to all securities of the Corporation
    which may be cast to elect directors of the Corporation, other than the acquisition of beneficial ownership of additional securities
    of the Corporation by any person who, together with persons acting jointly or in concert with such person, was entitled prior to
    such “take-over bid”, directly or following conversion or exercise securities of the Corporation, to cast more than fifty
    percent (50%) of the votes attaching to all securities of the Corporation which may be cast to elect directors of the Corporation;
	 	 	 
	 	(b)	the
    issuance to, or acquisition by, any person, or group of persons acting jointly or in concert, directly or indirectly, including through
    an arrangement or other form of reorganization, of beneficial ownership of securities of the Corporation which, directly or following
    conversion or exercise thereof, would entitle the holder thereof to cast more than fifty percent (50%) of the votes attaching to
    all securities of the Corporation which may be cast to elect directors of the Corporation, other than the issuance of securities
    of the Corporation to, or acquisition of securities of the Corporation by, any person who, together with persons acting jointly or
    in concert with such person, was entitled prior to such issuance or acquisition, directly or following conversion or exercise securities
    of the Corporation, to cast more than fifty percent (50%) of the votes attaching to all securities of the Corporation which may be
    cast to elect directors of the Corporation;
	 	 	 
	 	(c)	individuals
    who, as of a Grant Date, constitute the Board (the “Incumbent Board”) cease for any reason (other than death or
    disability) to constitute at least a majority of the Board; provided, however, that any individual becoming a Director subsequent
    to the Grant Date, whose election, or nomination for election by the Corporation’s shareholders, was approved by a vote of
    at least two-thirds of the Directors then comprising the Incumbent Board (either by a specific vote or by approval of the proxy statement
    of the Corporation in which such person is named as a nominee for Director, without objection to such nomination) will be considered
    as though such individual was a member of the Incumbent Board, but excluding for this purpose, any such individual whose initial
    assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of Directors
    or other actual or threatened solicitation of proxies or consents by or on behalf of a person other than the Directors then comprising
    the Board;

 

    	2

    	 

    

 

	 	(d)	an
    arrangement, amalgamation, merger or other form of reorganization of the Corporation where the holders of the outstanding voting
    securities or interests of the Corporation immediately prior to the completion of the arrangement, amalgamation, merger or reorganization
    will hold fifty percent (50%) or less of the votes attaching to all outstanding voting securities or interests of the continuing
    entity upon completion of the arrangement, amalgamation, merger or reorganization;
	 	 	 
	 	(e)	the
    sale of all or substantially all of the assets of the Corporation; or
	 	 	 
	 	(f)	the
    liquidation, winding-up or dissolution of the Corporation.

 

	 	1.3.9	“Code”
    or “Internal Revenue Code” means the United States Internal Revenue Code of 1986, as amended, and any applicable
    United States Treasury Regulations and other binding regulatory guidance thereunder.
	 	 	 
	 	1.3.10	“Corporation”
    means VBI Vaccines Inc. and includes any successor corporation thereof.
	 	 	 
	 	1.3.11	“Director”
    means a director of the Corporation from time to time.
	 	 	 
	 	1.3.12	“Disability”
    means:

 

	 	(a)	subject
    to (b) below, a Participant’s physical or mental incapacity that prevents him/her from substantially fulfilling his or her
    duties and responsibilities on behalf of the Corporation or, if applicable, an Affiliate, as determined by the Board and, in the
    case of a Participant who is an employee of the Corporation or an Affiliate, in respect of which the Participant commences receiving,
    or is eligible to receive, disability benefits under the Corporation’s or Affiliate’s long-term disability plan; or
	 	 	 
	 	(b)	where
    a Participant has a written employment agreement with the Corporation or an Affiliate, “Disability” as defined
    in such employment agreement, if applicable.

 

	 	1.3.13	“Disability
    Date” means, in relation to a Participant, that date determined by the Board to be the date on which the Participant experienced
    a Disability.
	 	 	 
	 	1.3.14	“Eligible
    Person” means an individual Employed by the Corporation or any Affiliate, including a Service Provider, who, by the nature
    of his or her position or job is, in the opinion of the Board, in a position to contribute to the success of the Corporation.

 

    	3

    	 

    

 

	 	1.3.15	“Employed”
    means, with respect to a Participant, that:

 

	 	(a)	the
    Participant is rendering services to the Corporation or an Affiliate (including services as a Director) including as a Service Provider
    (referred to in Section 1.3.43 as “active Employment”); or
	 	 	 
	 	(b)	the
    Participant is not actively rendering services to the Corporation or an Affiliate due to an approved leave of absence, maternity
    or parental leave or leave on account of Disability (provided, in the case of a US Taxpayer, that the Participant has not incurred
    a “Separation From Service”, within the meaning of Section 409A of the Code).
	 	 	 
	 	 	For
    greater certainty, a Participant shall not be considered to be Employed on a Vesting Date if, prior to such Vesting Date, such Participant
    received a payment in lieu of notice of termination of employment, whether under a contract of employment, as damages or otherwise.

 

and
“Employment’ has the corresponding meaning.

 

	 	1.3.16	“Exercise
    Price” means, (i) with respect to an Option, the price payable by a Participant to purchase one Share on exercise of such
    Option, which shall not be less than one hundred percent (100%) of the Market Price on the Grant Date of the Option covering such
    Share, and (ii) with respect to a Tandem SAR, the Exercise Price (as defined in paragraph (i) above) applicable to the Option to
    which the Tandem SAR relates, in each case subject to adjustment pursuant to Section 5.
	 	 	 
	 	1.3.17	“Grant”
    means a grant or right granted under the Plan consisting of one or more Options, Stock Appreciation Rights, RSUs or PSUs, shares
    of Restricted Stock or such other award as may be permitted hereunder.
	 	 	 
	 	1.3.18	“Grant
    Agreement” means an agreement between the Corporation and a Participant evidencing a Grant and setting out the terms under
    which such Grant is made, together with such schedules, amendments, deletions or changes thereto as are permitted under the Plan.
	 	 	 
	 	1.3.19	“Grant
    Date” means the effective date of a Grant.
	 	 	 
	 	1.3.20	“Incentive
    Stock Option” has the meaning ascribed thereto in Section 422(b) of the Code.
	 	 	 
	 	1.3.21	“Insider”
    means

 

(a)
a Director or officer of the Corporation;

 

(b)
a Director or officer of an Affiliate or a company that is an insider:

 

(c)
a person or company that has:

 

(i)
beneficial ownership of, or control or direction over, directly or indirectly, securities of the Corporation carrying more than 10 percent
of the voting rights attached to all the Corporation’s outstanding voting securities, excluding, for the purpose of the calculation
of the percentage held, any securities held by the person or company as underwriter in the course of a distribution, or

 

    	4

    	 

    

 

 

(ii)
a combination of beneficial ownership of, and control or direction over, directly or indirectly, securities of the Corporation carrying
more than 10 percent of the voting rights attached to all the Corporation’s outstanding voting securities, excluding, for the purpose
of the calculation of the percentage held, any securities held by the person or company as underwriter in the course of a distribution..

 

	 	1.3.22	“Market
    Price” means, with respect to any particular date:

 

	 	(a)	if
    the Shares are listed on only one Stock Exchange, the closing price per Share on such Stock Exchange;
	 	 	 
	 	(b)	if
    the Shares are listed on more than one Stock Exchange, the “Market Price” as determined in accordance with paragraph
    (a) above for the primary Stock Exchange on which the greatest volume of trading of the Shares occurred during the immediately preceding
    twenty (20) Trading Days; and
	 	 	 
	 	(c)	if
    the Shares are not listed for trading on a Stock Exchange, a price which is determined by the Board (acting on the advice of an independent
    third party, should the Board elect, in its sole discretion, to utilize an independent third party for this purpose), in good faith
    to be the fair market value of the Shares

 

	 	1.3.23	Notwithstanding
    the foregoing, the determination of the Market Price shall, where applicable to a US Taxpayer, be in compliance with Section 409A
    of the Code. “Option” means an option to purchase a Share granted by the Board to an Eligible Person in accordance
    with Section 3 and Section 9.1.
	 	 	 
	 	1.3.24	“Parent”
    means any parent corporation of the Corporation within the meaning of Code Section 424(e), or any successor provision.
	 	 	 
	 	1.3.25	“Participant”
    means an Eligible Person to whom a Grant is made and which Grant or a portion thereof remains outstanding.
	 	 	 
	 	1.3.26	“Performance
    Conditions” means such financial, personal, operational or transaction-based performance criteria as may be determined
    by the Board in respect of a Grant to any Participant or Participants and set out in a Grant Agreement. Performance Conditions may
    apply to the Corporation, an Affiliate, the Corporation and its Affiliates as a whole, a business unit of the Corporation or group
    comprised of the Corporation and some Affiliates or a group of Affiliates, either individually, alternatively or in any combination,
    and measured either in total, incrementally or cumulatively over a specified performance period, on an absolute basis or relative
    to a pre-established target or milestone, to previous years’ results or to a designated comparator group, or otherwise, provided
    that the performance period for measurement or achievement of any such performance criteria (or incremental element thereof) shall
    in all events exceed one year.

 

    	5

    	 

    

 

	 	1.3.27	“Performance
    Period” means, with respect to PSUs, the period specified by the Board for achievement of any applicable Performance Conditions
    as a condition to Vesting.
	 	 	 
	 	1.3.28	“Plan”
    means this VBI Vaccines Inc. Incentive Plan, including any schedules or appendices hereto, as may be amended from time to time.
	 	 	 
	 	1.3.29	“Performance
    Share Unit” or “PSU” means a right granted to an Eligible Person in accordance with Section 3 and Section
    14.1 to receive a Share or the Market Price, as determined by the Board, that generally becomes Vested, if at all, subject to the
    attainment of certain Performance Conditions and satisfaction of such other conditions to Vesting, if any, as may be determined by
    the Board.
	 	 	 
	 	1.3.30	“Restricted
    Share Unit” or “RSU” means a right granted to an Eligible Person in accordance with Section 3 and Section
    14.1 to receive a Share or the Market Price, as determined by the Board, that generally becomes Vested, if at all, following a period
    of continuous Employment of the Participant.
	 	 	 
	 	1.3.31	“Restricted
    Stock” means Shares granted to a Participant that are subject to a Restriction (as defined in Section 18).
	 	 	 
	 	1.3.32	“Restrictive
    Covenant” means any obligation of a Participant to the Corporation or an Affiliate to (A) maintain the confidentiality
    of information relating to the Corporation or the Affiliate and/or its business, (B) not engage in employment or business activities
    that compete with the business of the Corporation or the Affiliate, (C) not solicit employees or other service providers, customers
    and/or suppliers of the Corporation or the Affiliate, whether during or after employment with the Corporation or Affiliate, and whether
    such obligation is set out in a Grant Agreement issued under the Plan or other agreement between the Participant and the Corporation
    or Affiliate, including, without limitation, an employment agreement, or otherwise, or (D) any other restrictive covenant contained
    in an applicable Grant Agreement, employment agreement or other Agreement between a Participant and the Corporation or an Affiliate.
	 	 	 
	 	1.3.33	“Service
    Provider” means a person or company, other than an employee, officer or director of the Corporation or an Affiliate, that:

 

	 	(a)	is
    engaged to provide, on a bona fide basis, for an initial, renewable or extended period of twelve (12) months or more, services
    to the Corporation or an Affiliate, other than services provided in relation to a distribution of securities;
	 	 	 
	 	(b)	provides
    the services under a written contract between the Corporation or an Affiliate and the person or company; and
	 	 	 
	 	(c)	in
    the reasonable opinion of the Corporation, spends or will spend a significant amount of time and attention on the affairs and business
    of the Corporation or an Affiliate;
	 	 	 
	 	 	and
    includes

 

    	6

    	 

    

 

	 	(a)	for
    an individual Service Provider, a corporation of which the individual Service Provider is an employee or shareholder, and a partnership
    of which the individual Service Provider is an employee or partner; and
	 	 	 
	 	(b)	for
    a Service Provider that is not an individual, an employee, executive officer, or director of the Service Provider, provided that
    the individual employee, executive officer, or director spends or will spend a significant amount of time and attention on the affairs
    and business of the Corporation or an Affiliate.

 

	 	1.3.34	“Share”
    means a common share in the capital of the Corporation or, in the event of an adjustment contemplated by Section 5.1 hereof, such
    other security to which a Participant may be entitled upon the exercise or settlement of a Grant as a result of such adjustment.
	 	 	 
	 	1.3.35	“Share
    Unit” means either an RSU or a PSU, as the context requires.
	 	 	 
	 	1.3.36	“Stand-Alone
    SAR” means a Stock Appreciation right that is granted without reference to any related Option.
	 	 	 
	 	1.3.37	“Stock
    Appreciation Right” or “SAR” means a right, granted to an Eligible Person, representing the right to
    receive payment, in cash, Shares or any combination thereof, as determined by the Board, equal to the excess of the Market Price
    over the Base Price or Exercise Price, whichever is applicable, on the terms and conditions and calculated in accordance with the
    provisions of Section 10 hereof.
	 	 	 
	 	1.3.38	“Stock
    Exchange” means the NASDAQ Exchange and such other stock exchange on which the Shares are listed, or if the Shares are
    not listed on any stock exchange, then on the over-the-counter market.
	 	 	 
	 	1.3.39	“Stock
    Exchange Rules” means the applicable rules of any Stock Exchange upon which Shares of the Corporation are listed.
	 	 	 
	 	1.3.40	“Subsidiary”
    means, any subsidiary corporation of the Corporation within the meaning of Code Section 424(f), or any successor provision.
	 	 	 
	 	1.3.41	“Tandem
    SAR” means a Stock Appreciation Right attached to an Option, giving the holder, upon Vesting of the Option and Tandem SAR,
    the right to choose to exercise the Stock Appreciation Right or to exercise the Option.
	 	 	 
	 	1.3.42	“Termination”
    means (i) the termination of a Participant’s active Employment with the Corporation or an Affiliate (other than in connection
    with the Participant’s transfer to Employment with the Corporation or another Affiliate), which shall occur on the earlier
    of the date on which the Participant ceases to render services to the Corporation or Affiliate, as applicable, and the date on which
    the Corporation or an Affiliate, as applicable, delivers notice of the termination of the Participant’s employment or contract
    for services, whether such termination is lawful or otherwise, without giving effect to any period of notice or compensation in lieu
    of notice (except as expressly required by applicable employment standards legislation), but, for greater certainty, a Participant’s
    absence from active work during a period of vacation, temporary illness, authorized leave of absence, maternity or parental leave
    or leave on account of Disability shall not be considered to be a “Termination”, and (ii) in the case of a Participant
    who does not return to active Employment with the Corporation or an Affiliate immediately following a period of absence due to vacation,
    temporary illness, authorized leave of absence, maternity or parental leave or leave on account of Disability, such cessation shall
    be deemed to occur on the last day of such period of absence (provided, in each case, that, in the case of a US Taxpayer, the Termination
    constitutes a “Separation From Service”, within the meaning of Section 409A of the Code), and “Terminated”
    and “Terminates” shall be construed accordingly.

 

    	7

    	 

    

 

	 	1.3.43	“Time
    Vesting” means any conditions relating to the passage of time or continued service with the Corporation or an Affiliate
    for a period of time in respect of a Grant, as may be determined by the Board.
	 	 	 
	 	1.3.44	“Trading
    Day” means a day on which the Stock Exchange is open for trading and on which the Shares actually traded.
	 	 	 
	 	1.3.45	“US
    Taxpayer” means an individual who is subject to tax under the Code in respect of any amounts payable or Shares deliverable
    under this Plan.
	 	 	 
	 	1.3.46	“Vested”
    means, with respect to any Option, SAR, Share Unit, share of Restricted Stock or other award included in a Grant, that the applicable
    conditions with respect to Time Vesting, achievement of Performance Conditions and/or any other conditions established by the Board
    have been satisfied or, to the extent permitted under the Plan, waived, whether or not the Participant’s rights with respect
    to such Grant may be conditioned upon prior or subsequent compliance with any Restrictive Covenants (and any applicable derivative
    term shall be construed accordingly).
	 	 	 
	 	1.3.47	“Vesting
    Date” means the date on which the applicable Time Vesting, Performance Conditions and/or any other conditions for an Option,
    SAR, Share Unit, share of Restricted Stock or other award included in a Grant becoming Vested are met, deemed to have been met or
    waived as contemplated in Section 3.1.

 

	2.	CONSTRUCTION
    AND INTERPRETATION

 

	 	2.1	Gender,
    Singular, Plural.

 

In
the Plan, references to the masculine include the feminine; and references to the singular shall include the plural and vice versa, as
the context shall require.

 

	 	2.2	Severability.

 

If
any provision or part of the Plan is determined to be void or unenforceable in whole or in part, such determination shall not affect
the validity or enforcement of any other provision or part thereof.

 

    	8

    	 

    

 

	 	2.3	Headings,
    Sections and Parts.

 

Headings
wherever used herein are for reference purposes only and do not limit or extend the meaning of the provisions herein contained. A reference
to a section or schedule shall, except where expressly stated otherwise, mean a section or schedule of the Plan, as applicable. The Plan
is divided into four Parts. Part I contains provisions of general application to all Grants; Part II applies specifically to Options
and SARs; Part III applies specifically to Share Units; and Part IV applies specifically to Restricted Stock and other Share-based awards.

 

	 	2.4	Insiders.

 

With
respect to Insiders, the Plan and all transactions under the Plan are intended to comply with all applicable conditions of Rule 16b-3
promulgated under the U.S. Securities Exchange Act of 1934, as amended. To the extent any provision of the Plan or action by the Board
fails to so comply, such provision or action shall be deemed null and void ab initio, to the extent permitted by Applicable Law
and deemed advisable by the Board.

 

	3.	ADMINISTRATION

 

	 	3.1	Administration
    by the Board.

 

The
Plan shall be administered by the Board in accordance with its terms and subject to Applicable Law. Subject to and consistent with the
terms of the Plan, in addition to any authority of the Board specified under any other terms of the Plan, the Board shall have full and
complete discretionary authority to:

 

	 	(a)	interpret
    the Plan and Grant Agreements;
	 	 	 
	 	(b)	prescribe,
    amend and rescind such rules and regulations and make all determinations necessary or desirable for the administration and interpretation
    of the Plan and instruments of grant evidencing Grants;
	 	 	 
	 	(c)	determine
    those Eligible Persons who may receive Grants as Participants, grant one or more Grants to such Participants and approve or authorize
    the applicable form and terms of the related Grant Agreement;
	 	 	 
	 	(d)	determine
    the terms and conditions of Grants granted to any Participant, including, without limitation, as applicable (i) Grant Value and the
    number of Shares subject to a Grant, (ii) the Exercise Price or Base Price for Shares subject to a Grant, (iii) the conditions to
    the Vesting of a Grant or any portion thereof, including, as applicable, the period for achievement of any applicable Performance
    Conditions as a condition to Vesting and conditions pertaining to compliance with Restrictive Covenants, and the conditions, if any,
    upon which Vesting of any Grant or any portion thereof will be waived or accelerated without any further action by the Board, (iv)
    the circumstances upon which a Grant or any portion thereof shall be forfeited, cancelled or expire, including in connection with
    the breach by a Participant of any Restrictive Covenant, (v) the consequences of a Termination with respect to a Grant, (vi) the
    manner of exercise or settlement of the Vested portion of a Grant, (vii) whether, and the terms upon which, a Grant may be settled
    in cash, newly issued Shares or a combination thereof, and (viii) whether, and the terms upon which, any Shares delivered upon exercise
    or settlement of a Grant must be held by a Participant for any specified period of time;

 

    	9

    	 

    

 

	 	(e)	determine
    whether, and the extent to which, any Performance Conditions or other conditions applicable to the Vesting of a Grant have been satisfied
    or shall be waived or modified;
	 	 	 
	 	(f)	make
    such rules, regulations and determinations as it deems appropriate under the Plan in respect of any leave of absence or disability
    of any Participant. Without limiting the generality of the foregoing, the Board shall be entitled to determine:

 

	 	(i)	whether
    or not any such leave of absence shall constitute a Termination within the meaning of the Plan;
	 	 	 
	 	(ii)	the
    impact, if any, of any such leave of absence on Grants issued under the Plan made to any Participant who takes such leave of absence
    (including, without limitation, whether or not such leave of absence shall cause any Grants to expire and the impact upon the time
    or times such Grants shall be exercisable);
	 	 	 
	 	 	provided
    that, with respect to Options that are intended to be Incentive Stock Options, the treatment of any such leave of absence shall comply
    with Code Section 422 and the regulations issued thereunder;

 

	 	(g)	amend
    the terms of any Grant Agreement or other documents evidencing Grants; and
	 	 	 
	 	(h)	determine
    whether, and the extent to which, adjustments shall be made pursuant to Section 5 and the terms of such adjustments.

 

	 	3.2	All
    determinations, interpretations, rules, regulations, or other acts of the Board respecting the Plan or any Grant shall be made in
    its sole discretion and shall be conclusively binding upon all persons.
	 	 	 
	 	3.3	The
    Board may prescribe terms for Grant Agreements in respect of Eligible Persons who are subject to the laws of a jurisdiction other
    than Canada in connection with their participation in the Plan that are different than the terms of the Grant Agreements for Eligible
    Persons who are subject to the laws of Canada in connection with their participation in the Plan, and/or deviate from the terms of
    the Plan set out herein, for purposes of compliance with Applicable Law in such other jurisdiction or where, in the Board’s
    opinion, such terms or deviations are necessary or desirable to obtain more advantageous treatment for the Corporation, an Affiliate
    or the Eligible Person in respect of the Plan under the Applicable Law of the other jurisdiction.
	 	 	 
	 	 	Notwithstanding
    the foregoing, the terms of any Grant Agreement authorized pursuant to this Section 3.3 shall be consistent with the Plan to the
    extent practicable having regard to the Applicable Law of the jurisdiction in which such Grant Agreement is applicable and in no
    event shall contravene the Applicable Law of Canada, except as otherwise provided in Section 7.9 or Exhibit A or Exhibit B attached
    hereto.

 

    	10

    	 

    

 

	 	3.4	The
    Board may, in its discretion, subject to Applicable Law, delegate its powers, rights and duties under the Plan, in whole or in part,
    to a committee of the Board, a person or persons, as it may determine, from time to time, on terms and conditions as it may determine,
    except that the Board shall not, and shall not be permitted to delegate any such powers, rights or duties (i) with respect to the
    grant, amendment, administration or settlement of any Grant to the extent delegation is not consistent with Applicable Law and any
    such purported delegation or action shall not be given effect, and (ii) provided that the composition of the committee of the Board,
    person or persons, as the case may be, shall comply with Applicable Law. In addition, provided it complies with the foregoing, the
    Board may appoint or engage a trustee, custodian or administrator to administer or implement the Plan or any aspect of it. Notwithstanding
    the foregoing, to the extent necessary to satisfy the requirements of Rule 16b-3 promulgated under the U.S. Securities Exchange Act
    of 1934, as amended, any function relating to an Insider shall be performed solely by the Board.

 

	4.	SHARE
    RESERVE

 

	 	4.1	Subject
    to Section 4.4 and any adjustment pursuant to Section 5.1, the aggregate number of Shares that may be issued pursuant to Grants made
    under the Plan together with any other security-based compensation arrangement of the Corporation, shall not exceed ten percent (10%)
    of the aggregate issued and outstanding Shares from time to time (on a non-diluted basis).
	 	 	 
	 	4.2	The
    aggregate number of Shares reserved for issuance to any one Participant under the Plan, together with all other security-based compensation
    arrangements of the Corporation, must not exceed five percent (5%) of the aggregate issued and outstanding Shares (on a non-diluted
    basis).
	 	 	 
	 	4.3	The
    maximum number of Shares of the Corporation

 

	 	(a)	issued
    to Insiders within any one-year period, and
	 	 	 
	 	(b)	issuable
    to Insiders, at any time,

 

	 	 	under
    the Plan, or when combined with all of the Corporation’s other security-based compensation arrangements, shall not exceed ten
    percent (10%) of the number of the aggregate issued and outstanding Shares.
	 	 	 
	 	4.4	For
    purposes of computing the total number of Shares available for grant under the Plan or any other security-based compensation arrangement
    of the Corporation, Shares subject to any Grant (or any portion thereof) that is forfeited, surrendered, cancelled or otherwise terminated
    prior to the issuance of such Shares shall again be available for grant under the Plan.

 

    	11

    	 

    

 

	5.	Alteration
    of Capital And Change In Control

 

	 	5.1	Notwithstanding
    any other provision of the Plan, and subject to Applicable Law, in the event of any change in the Shares by reason of any dividend
    (other than dividends in the ordinary course), split, recapitalization, reclassification, amalgamation, arrangement, merger, consolidation,
    combination or exchange of Shares or distribution of rights to holders of Shares or any other relevant changes to the authorized
    or issued capital of the Corporation, if the Board shall determine that an equitable adjustment should be made, such adjustment shall,
    subject to Applicable Law, be made by the Board to (i) the number of Shares subject to the Plan; (ii) the securities into which the
    Shares are changed or are convertible or exchangeable; (iii) any Options and/or Stock Appreciation Rights then outstanding; (iv)
    the Exercise Price and/or Base Price, as appropriate in respect of such Options and/or Stock Appreciation Rights; and/or (v) with
    respect to the number of Share Units outstanding under the Plan, and any such adjustment shall be conclusive and binding for all
    purposes of the Plan. Notwithstanding the foregoing, no such adjustment shall be made or authorized to the extent that such adjustment
    would cause the Plan or any award to violate Section 422 of the Code or Section 409A of the Code.
	 	 	 
	 	5.2	No
    adjustment provided for pursuant to Section 5.1 shall require the Corporation to issue fractional Shares in satisfaction of its obligations
    under the Plan. Any fractional interest in a Share that would, except for the provisions of this Section 5.2, be deliverable upon
    the exercise of any Grant shall be cancelled and not deliverable by the Corporation.
	 	 	 
	 	5.3	In
    the event of a Change in Control prior to the Vesting of a Grant, and subject to the terms of a Participant’s written employment
    agreement or contract for services with the Corporation or an Affiliate and the applicable Grant Agreement, the Board shall have
    full authority to determine in its sole discretion the effect, if any, of a Change in Control on the Vesting, exercisability, settlement,
    payment or lapse of restrictions applicable to a Grant, which effect may be specified in the applicable Grant Agreement or determined
    at a subsequent time. Subject to Applicable Law, rules and regulations, the Board shall, at any time prior to, coincident with or
    after the effective time of a Change in Control, take such actions as it may consider appropriate, including, without limitation:
    (i) provide for the acceleration of any Vesting or exercisability of a Grant; (ii) provide for the deemed attainment of Performance
    Conditions relating to a Grant; (iii) provide for the lapse of restrictions relating to a Grant; (iv) provide for the assumption,
    substitution, replacement or continuation of any Grant by a successor or surviving corporation (or a parent or subsidiary thereof)
    with cash, securities, rights or other property to be paid or issued, as the case may be, by the successor or surviving corporation
    (or a parent or subsidiary thereof); (v) provide that that a Grant shall terminate or expire unless exercised or settled in full
    on or before a date fixed by the Board; or (vi) terminate or cancel any outstanding Grant in exchange for a cash payment (provided
    that, if as of the date of the Change in Control, the Board determines that no amount would have been realized upon the exercise
    or settlement of the Grant, then the Grant may be cancelled by the Corporation without payment of consideration). Notwithstanding
    the foregoing, no such adjustment shall be made or authorized to the extent that such adjustment would cause the Plan or any award
    to violate Section 422 of the Code or Section 409A of the Code.

 

	6.	clawback

 

	 	6.1	Clawback.

 

It
is a condition of each Grant that if:

 

(i)
the Participant fails to comply with any applicable Restrictive Covenant;

 

    	12

    	 

    

 

(ii)
the Participant is terminated for Cause, or the Board reasonably determines after employment termination that the Participant’s
employment could have been terminated for Cause;

 

(iii)
the Board reasonably determines that the Participant engaged in conduct that causes material financial or reputational harm to the Corporation
or its Affiliates, or engaged in gross negligence, willful misconduct or fraud in respect of the performance of the Participant’s
duties for the Corporation or an Affiliate of the Corporation; or

 

(iv)
the Corporation’s financial statements (the “Original Statements”) are required to be restated (other than solely as
a result of a change in accounting policy by the Corporation or under International Financial Reporting Standards applicable to the Corporation)
and such restated financial statements (the “Restated Statements”) disclose, in the opinion of the Board acting reasonably,
materially worse financial results than those contained in the Original Statements,

 

then
the Board may, in its sole discretion, to the full extent permitted by governing law and to the extent it determines that such action
is in the best interest of the Corporation, and in addition to any other rights that the Corporation or an Affiliate may have at law
or under any agreement, take any or all of the following actions, as applicable:

 

(a)
require the Participant to reimburse the Corporation for any amount paid to the Participant in respect of a Grant in cash in excess of
the amount that should otherwise have been paid in respect of such Grant had the determination of such compensation been based upon the
Restated Statements in the event clause (iv) above is applicable, or that was paid in the twelve (12) months prior to (x) the date on
which the Participant fails to comply with a Restrictive Covenant, (y) the date on which the Participant’s employment is terminated
for Cause, or the Board makes a determination under paragraph (ii) or (iii) above, less, in any event, the amount of tax withheld pursuant
to the Income Tax Act (Canada) or other relevant taxing authority in respect of the amount paid in cash in the year of payment;

 

(b)
reduce the number or value of, or cancel and terminate, any one or more unvested Grants of Options, Share Units or SARs on or prior to
the applicable maturity or Vesting Dates, or cancel or terminate any outstanding Grants which have Vested in the twelve (12) months prior
to (x) the date on which the Participant fails to comply with a Restrictive Covenant, (y) the date on which the Participant’s employment
is terminated for Cause or the Board makes a determination under paragraph (ii) or (iii) above, or (z) the date on which the Board determines
that the Corporation’s Original Statements are required to be restated, in the event paragraph (iv) above applies (each such date
provided for in clause (x), (y) and (z) of this paragraph (b) being a “Relevant Equity Recoupment Date”); and/or

 

(c)
require payment to the Corporation of the value of any Shares of the Corporation acquired by the Participant pursuant to a Grant in the
twelve (12) months prior to a Relevant Equity Recoupment Date (less any amount paid by the Participant to acquire such Shares and less
the amount of tax withheld pursuant to the Income Tax Act (Canada) or other relevant taxing authority in respect of such Shares).

 

    	13

    	 

    

 

	7.	MISCELLANEOUS

 

	 	7.1	Compliance
    with Laws and Policies.

 

The
Corporation’s obligation to make any payments or deliver (or cause to be delivered) any Shares hereunder is subject to compliance
with Applicable Law. Each Participant shall acknowledge and agree (and shall be conclusively deemed to have so acknowledged and agreed
by participating in the Plan) that the Participant will, at all times, act in strict compliance with Applicable Law and all other laws
and any policies of the Corporation applicable to the Participant in connection with the Plan including, without limitation, furnishing
to the Corporation all information and undertakings as may be required to permit compliance with Applicable Law.

 

	 	7.2	Withholdings.

 

So
as to ensure that the Corporation or an Affiliate, as applicable, will be able to comply with the applicable obligations under any federal,
provincial, state or local law relating to the withholding of tax or other required deductions, the Corporation or the Affiliate shall
withhold or cause to be withheld from any amount payable to a Participant, either under this Plan, or otherwise, such amount as may be
necessary to permit the Corporation or the Affiliate, as applicable, to so comply. The Corporation and any Affiliate may also satisfy
any liability for any such withholding obligations, on such terms and conditions as the Corporation may determine in its sole discretion,
by (a) selling on such Participant’s behalf, or requiring such Participant to sell, any Shares, and retaining any amount payable
which would otherwise be provided or paid to such Participant in connection with any such sale, or (b) requiring, as a condition to the
delivery of Shares hereunder, that such Participant make such arrangements as the Corporation may require so that the Corporation and
its Affiliates can satisfy such withholding obligations, including requiring such Participant to remit an amount to the Corporation or
an Affiliate in advance, or reimburse the Corporation or any Affiliate for, any such withholding obligations.

 

	 	7.3	No
    Right to Continued Employment.

 

Nothing
in the Plan or in any Grant Agreement entered into pursuant hereto shall confer upon any Participant the right to continue in the employ
or service of the Corporation or any Affiliate, to be entitled to any remuneration or benefits not set forth in the Plan or a Grant Agreement
or to interfere with or limit in any way the right of the Corporation or any Affiliate to terminate Participant’s employment or
service arrangement with the Corporation or any Affiliate.

 

	 	7.4	No
    Additional Rights.

 

Neither
the designation of an individual as a Participant nor the Grant of any Options, SARs, Share Units, Restricted Stock or other award to
any Participant entitles any person to the Grant, or any additional Grant, as the case may be, of any Options, SARs, Share Units, Restricted
Stock or other award under the Plan. For greater certainty, the Board’s decision to approve a Grant in any period shall not require
the Board to approve a Grant to any Participant in any other period; nor shall the Board’s decision with respect to the size or
terms and conditions of a Grant in any period require it to approve a Grant of the same or similar size or with the same or similar terms
and conditions to any Participant in any other period. The Board shall not be precluded from approving a Grant to any Participant solely
because such Participant may have previously received a Grant under this Plan or any other similar compensation arrangement of the Corporation
or an Affiliate. No Eligible Person has any claim or right to receive a Grant except as may be provided in a written employment or services
agreement between an Eligible Person and the Corporation or an Affiliate.

 

    	14

    	 

    

 

	 	7.5	Amendment,
    Termination.

 

The
Plan and any Grant made pursuant to the Plan may be amended, modified or terminated by the Board without approval of shareholders, provided
that no amendment to the Plan or Grants made pursuant to the Plan may be made without the consent of a Participant if it adversely alters
or impairs the rights of the Participant in respect of any Grant previously granted to such Participant under the Plan, except that Participant
consent shall not be required where the amendment is required for purposes of compliance with Applicable Law. For greater certainty,
the Plan may not be amended without shareholder approval in accordance with the requirements of the Stock Exchange to do any of the following:

 

	 	(a)	increase
    in the maximum number of Shares issuable pursuant to the Plan and as set out in Section 4.1;
	 	 	 
	 	(b)	reduce
    the Exercise Price of an outstanding Option or the Base Price of a Stand-Alone SAR, including a cancellation of a Grant of an Option
    and re-grant within six (6) months of an Option in conjunction therewith constituting a reduction of the Exercise Price of the Option;
	 	 	 
	 	(c)	extend
    the maximum term of any Grant made under the Plan;
	 	 	 
	 	(d)	amend
    the assignment provisions contained in Section 7.11 or Section 12;
	 	 	 
	 	(e)	increase
    the number of Shares that may be issued or issuable to Insiders above the restriction or deleting the restriction on the number of
    Shares that may be issued or issuable to Insiders contained in Section 4.3;
	 	 	 
	 	(f)	include
    other types of equity compensation involving the issuance of Shares under the Plan;
	 	 	 
	 	(g)	cause
    Incentive Stock Options to fail to meet the requirements of Code Section 422; or
	 	 	 
	 	(h)	amend
    this Section 7.5 to amend or delete any of (a) through (h) above or grant additional powers to the Board to amend the Plan or entitlements
    without shareholder approval.

 

For
greater certainty and without limiting the foregoing, shareholder approval shall not be required for the following amendments and the
Board may make the following changes without shareholder approval, subject to any regulatory approvals including, where required, the
approval of any Stock Exchange:

 

	 	(i)	amendments
    of a “housekeeping” nature;
	 	 	 
	 	(j)	a
    change to the Vesting provisions of any Grants;

 

    	15

    	 

    

 

	 	(k)	a
    change to the termination provisions of any Grant that does not entail an extension beyond the original term of the Grant; or
	 	 	 
	 	(l)	amendments
    to the provisions relating to a Change in Control.

 

	 	7.6
    	Currency.
    Except where the context otherwise requires, all references in the Plan to currency refer to
    lawful United States currency. Any amounts required to be determined under this Plan that are denominated in a currency other than
    United States dollars shall be converted to United States dollars at the applicable Federal Reserve noon rate of exchange on the
    date as of which the amount is required to be determined.

 

	 	7.7	Administration
    Costs.

 

The
Corporation will be responsible for all costs relating to the administration of the Plan.

 

	 	7.8	Designation
    of Beneficiary.

 

Subject
to the requirements of Applicable Law, a Participant may designate a Beneficiary, in writing, to receive any benefits that are provided
under the Plan upon the death of such Participant. The Participant may, subject to Applicable Law, change such designation from time
to time. Such designation or change shall be in such form as may be prescribed by the Board from time to time. A Beneficiary designation
under this Section 7.8 and any subsequent changes thereto shall be filed with the General Counsel of the Corporation.

 

	 	7.9	Governing
    Law.

 

The
Plan and any Grants pursuant to the Plan shall be governed by and construed in accordance with the laws of the Province of British Columbia
and the federal laws of Canada applicable therein, and with respect to Participants who are US Taxpayers, with the Code and applicable
federal laws of the US. The Board may provide that any dispute to any Grant shall be presented and determined in such forum as the Board
may specify, including through binding arbitration. Any reference in the Plan, in any Grant Agreement issued pursuant to the Plan or
in any other agreement or document relating to the Plan to a provision of law or rule or regulation shall be deemed to include any successor
law, rule or regulation of similar effect or applicability. To the extent applicable, with respect to Participants who are US Taxpayers,
this Plan shall be interpreted in accordance with the requirements of Code Sections 409A and the regulations, notices, and other guidance
of general applicability issued thereunder.

 

	 	7.10	Assignment.

 

The
Plan shall inure to the benefit of and be binding upon the Corporation, its successors and assigns.

 

	 	7.11	Transferability.

 

	 	7.11.1	Unless
    otherwise provided in the Plan or in the applicable Grant Agreement in accordance with Section 7.11.2, no Grant, and no rights or
    interests therein, shall or may be assigned, transferred, sold, exchanged, encumbered, pledged or otherwise hypothecated or disposed
    of by a Participant other than by testamentary disposition by the Participant or the laws of intestate succession. No such interest
    shall be subject to execution, attachment or similar legal process including without limitation seizure for the payment of the Participant’s
    debts, judgments, alimony or separate maintenance.

 

    	16

    	 

    

 

	 	7.11.2	Notwithstanding
    the foregoing, with respect to Participants who are not US Taxpayers, the Board may provide in the applicable Grant Agreement that
    a Grant is transferable or assignable (a) in the case of a transfer without the payment of any consideration, to the Participant’s
    spouse, former spouse, children, stepchildren, grandchildren, parent, stepparent, grandparent, sibling, persons having one of the
    foregoing types of relationship with a Participant due to adoption and any entity in which these persons (or the Participant) own
    more than fifty percent (50%) of the voting interests and (b) to an entity in which more than fifty percent (50%) voting interests
    are owned by these persons (or the Participant) in exchange for an interest in that entity. Following any such transfer or assignment,
    the Grant shall remain subject to substantially the same terms applicable to the Grant while held by the Participant to whom it was
    granted, as modified as the Board shall determine appropriate, and, as a condition to such transfer, the transferee shall execute
    an agreement agreeing to be bound by such terms. Any purported assignment or transfer that does not qualify under this Section 7.11.2
    shall be void and unenforceable against the Corporation.

 

	8.	EFFECTIVE
    DATE

 

	 	8.1	The
    Plan is established effective May 6, 2016,
    as amended effective as of _____, 2021.

 

    	17

    	 

    

 

PART
II – OPTIONS AND SARS

 

	9.	Options

 

	 	9.1	The
    Corporation may, from time to time, make one or more Grants of Options to Eligible Persons on such terms and conditions, consistent
    with the Plan, as the Board shall determine. In granting such Options, subject to the provisions of the Plan, the Corporation shall
    specify,

 

	 	(a)	the
    maximum number of Shares which the Participant may purchase under the Options;
	 	 	 
	 	(b)	the
    Exercise Price at which the Participant may purchase his or her Shares under the Options;
	 	 	 
	 	(c)	the
    term of the Options, to a maximum of ten years from the Grant Date of the Options, the Vesting period or periods within this period
    during which the Options or a portion thereof may be exercised by a Participant and any other Vesting conditions (including Performance
    Conditions); and
	 	 	 
	 	(d)	any
    Tandem SARs that are granted with respect to such Options.

 

	 	9.2	The
    Exercise Price for each Share subject to an Option shall be fixed by the Board but under no circumstances shall any Exercise Price
    be less than one hundred percent (100%) of the Market Price on the Grant Date of such Option.
	 	 	 
	 	9.3	Unless
    otherwise designated by the Board in the applicable Grant Agreement, twenty five percent (25%) of the Options included in a Grant
    shall Vest on each of the first four anniversaries of the Grant Date and, subject to Section 9.5, any such Options shall expire on
    the tenth anniversary of the Grant Date (unless exercised or terminated earlier in accordance with the terms of the Plan or the Grant
    Agreement).
	 	 	 
	 	9.4	Subject
    to the provisions of the Plan and the terms governing the granting of the Option, and subject to payment or other satisfaction of
    all related withholding obligations in accordance with Section 7.2 hereof, Vested Options or a portion thereof may be exercised from
    time to time by delivery to the Corporation at its registered office of a notice in writing signed by the Participant or the Participant’s
    legal personal representative, as the case may be, and addressed to the Corporation. This notice shall state the intention of the
    Participant or the Participant’s legal personal representative to exercise the said Options and the number of Shares in respect
    of which the Options are then being exercised and must be accompanied by payment in full of the Exercise Price under the Options
    which are the subject of the exercise. On the exercise of an Option, any related Tandem SAR shall be cancelled.

 

    	18

    	 

    

 

	 	9.5	If
    the normal expiry date of any Option, other than an Incentive Stock Option, falls within any Blackout Period or within ten business
    days (being a day other than a Saturday, Sunday or other than a day when banks in Vancouver, British Columbia are not generally open
    for business) following the end of any Blackout Period, then the expiry date of such Option shall, without any further action, be
    extended to the date that is ten business days following the end of such Blackout Period. The foregoing extension applies to all
    Options whatever the Grant Date (other than Incentive Stock Options and other than an extension beyond the original term of the Options
    in the case of Options held by a US Taxpayer) and shall not be considered an extension of the term of the Options as referred to
    in Section 7.5 hereof.
	 	 	 
	 	9.6	Notwithstanding
    anything in this Plan to the contrary, for Options that are intended to qualify as Incentive Stock Options and granted to a US Taxpayer,
    the following additional provisions will apply:

 

	 	(a)	Except
    as permitted by Code Section 424(a), or any successor provision, the Exercise Price per Share shall not be less than one hundred
    percent (100%) of the per Share Market Price on the Effective Date of the Incentive Stock Option; provided, however, that if a Participant
    owns shares possessing more than ten percent (10%) of the total combined voting power of all classes of shares of the Corporation
    or of its Parent or any Subsidiary, the Exercise Price per Share of an Incentive Stock Option granted to such Participant shall not
    be less than one hundred ten percent (110%) of the Market Price on the Effective Date of the Incentive Stock Option.
	 	 	 
	 	(b)	Except
    as permitted by Code Section 424(a), in no event shall any Incentive Stock Option be exercisable during a term of more than ten (10)
    years after the Effective Date of the Incentive Stock Option; provided, however, that if a Participant owns shares possessing more
    than ten percent (10%) of the total combined voting power of all classes of shares of the Corporation or of its Parent or any Subsidiary,
    the Incentive Stock Option granted to such Participant shall be exercisable during a term of not more than five (5) years after the
    Effective Date.
	 	 	 
	 	(c)	The
    Corporation or its Affiliate shall be entitled to withhold and deduct from any future payments to the Participant all legally required
    amounts necessary to satisfy any and all withholding and employment-related taxes attributable to the Participant’s exercise
    of an Incentive Stock Option or a “disqualifying disposition” of Shares acquired through the exercise of an Incentive
    Stock Option as defined in Code Section 421(b) or require the Participant to remit an amount sufficient to satisfy such withholding
    requirements, or any combination thereof.
	 	 	 
	 	(d)	Notwithstanding
    any other provision of the Plan, the aggregate fair market value (determined as of the Effective Date of the Incentive Stock Option)
    of the Shares with respect to which Incentive Stock Options are exercisable for the first time by a Participant during any calendar
    year under the Plan and any other “incentive stock option” plans of the Corporation or any Affiliate, shall not exceed
    US$100,000 (or such other amount as may be prescribed by the Code from time to time); provided, however, that if the exercisability
    or Vesting of an Incentive Stock Option is accelerated as permitted under the provisions of the Plan and such acceleration would
    result in a violation of the limit imposed by this Section 9.6 (d), such acceleration shall be of full force and effect but the number
    of Shares that exceed such limit shall be treated as having been granted pursuant to a Nonqualified Stock Option; and provided, further,
    that the limits imposed by this Section 9.6 (d) shall be applied to all outstanding Incentive Stock Options under the Plan and any
    other “incentive stock option” plans of the Corporation or any Affiliate in chronological order according to the dates
    of grant.

 

    	19

    	 

    

 

	 	(e)	The
    Grant Agreement in respect of any Incentive Stock Option shall contain such other limitations and restrictions upon the exercise
    of the Incentive Stock Option as the Board shall deem necessary to ensure that such Incentive Stock Option will be considered an
    “incentive stock option” as defined in Code Section 422 or to conform to any change therein.
	 	 	 
	 	(f)	One
    hundred percent (100%) of the Shares reserved and available under the Plan pursuant to Section 4.1 shall constitute the maximum aggregate
    number of Shares that may be issued through Incentive Stock Options.

 

	10.	Stock
    Appreciation Rights

 

	 	10.1	The
    Board may from time to time make one or more Grants of Stock Appreciation Rights to Eligible Persons on such terms and conditions,
    consistent with the Plan, as the Board shall determine.
	 	 	 
	 	10.2	Tandem
    SARs may be granted at or after the Grant Date of the related Options, and each Tandem SAR shall be subject to the same terms and
    conditions and denominated in the same currency as the Option to which it relates and the additional terms and conditions set forth
    in this Section 10.
	 	 	 
	 	10.3	On
    exercise of a Tandem SAR, the related Option shall be cancelled and the Participant shall be entitled to an amount in settlement
    of such Tandem SAR calculated and in such form as provided in Section 10.8 below.
	 	 	 
	 	10.4	Tandem
    SARs may be exercised only if and to the extent the Options related thereto are then Vested and exercisable and shall be exercised
    in accordance with such procedures as may be established by the Board. For greater certainty, upon the expiry or forfeiture of the
    Option to which a Tandem SAR is attached, including in connection with a Participant’s Termination, as provided in Section
    11, such Tandem SAR shall also expire or be forfeited, as the case may be.
	 	 	 
	 	10.5	Stand-Alone
    SARs granted under the Plan shall become Vested at such times, in such installments and subject to the terms and conditions of this
    Plan (including satisfaction of Performance Conditions and/or continued employment) as may be determined by the Board and set forth
    in the applicable Grant Agreement. For greater certainty, except as set out in a Grant Agreement in respect of the Stand-Along SAR,
    no Stand-Alone SAR granted to a Participant shall Vest after the Participant’s Termination and any Stand-Alone SARs that are
    outstanding on the Participant’s date of Termination shall be forfeited and cancelled as of such date.
	 	 	 
	 	10.6	The
    Base Price for each Stand-Alone SAR shall not be less that one hundred percent of the Market Price on the Grant Date of such Stand-Alone
    SAR.
	 	 	 
	 	10.7	Unless
    the Board determines otherwise, Stand-Alone SARs covered by a Grant shall, when and to the extent Vested, be settled by payment in
    cash of the amount determined in accordance with Section 10.8.

 

    	20

    	 

    

 

	 	10.8	Upon
    exercise thereof, or the settlement thereof in accordance with Section 10.7, and subject to payment or other satisfaction of all
    related withholding obligations in accordance with Section 7.2 hereof, Stock Appreciation Rights (and, in the case of Tandem SARs,
    the related Options) shall be settled by payment in cash, of an amount, or the delivery of Shares or a combination of cash and Shares,
    as determined by the Board with an aggregate value equal to the product of:

 

	 	(A)	the
    excess of the Market Price on the date of exercise over the Exercise Price or Base Price under the applicable Stock Appreciation
    Right,
	 	 	 
	 	 	multiplied
    by
	 	 	 
	 	(B)	the
    number of Stock Appreciation Rights exercised or settled.

 

	 	10.9	Any
    cash payment in settlement of a Stand-Alone SAR shall be payable in United States dollars. Any cash payment in settlement of a Tandem
    SAR shall be payable in the currency as the option to which it relates. Any portion of a Stock Appreciation Right that is to be settled
    in Shares shall be settled by delivery of the number of Shares having a Market Price on the date of exercise equal to the portion
    of the amount determined in accordance with Section 10.8 being settled, rounded down to the nearest whole Share.
	 	 	 
	 	10.10	If
    the normal expiry date of any Stock Appreciation Right falls within any Blackout Period or within ten business days (being a day
    other than a Saturday, Sunday or other than a day when banks in Vancouver, British Columbia are not generally open for business)
    following the end of any Blackout Period, then the expiry date of such Stock Appreciation Right shall, without any further action,
    be extended to the date that is ten business days following the end such Blackout Period. The foregoing extension applies to all
    SARs whatever, other than Tandem SARs attached to Options of a US Taxpayer which shall be governed by the provisions of Section 9.5
    that apply to the related Options, and shall not be considered an extension of the term of the SARs as referred to in Section 7.5
    hereof.

 

	11.	Termination
    of Employment and Death of a Participant – Options and Tandem SARs

 

	 	11.1	Outstanding
    Options held by a Participant (or the executors or administrators of such Participant’s estate, any person or persons who acquire
    the right to exercise Options directly from the Participant by bequest or inheritance or any other permitted transferee of the Participant
    under Section 12 hereof) as of the Participant’s date of Termination shall be subject to the provisions of this Section 11,
    as applicable; except that, in all events, the period for exercise of Options shall end no later than the last day of the maximum
    term thereof established under Section 9.1(c), 9.5, 9.6(b) or 11.5, as the case may be.
	 	 	 
	 	11.2	Subject
    to the applicable Grant Agreement, Section 11.1 and Section 11.6, in the case of a Participant’s Termination due to death,
    or in the case of the Participant’s Disability (i) those of the Participant’s outstanding Options that were granted prior
    to the year that includes the Participant’s date of death or Disability Date, as the case may be, that have not become Vested
    prior to such date of death or Disability Date shall continue to Vest and, upon Vesting, be exercisable during the thirty-six (36)
    month period following such date of death or Disability Date, as the case may be, as if the Participant had remained Employed throughout
    such period and (ii) those of the Participant’s outstanding Options that have become Vested prior to the Participant’s
    date of death or Disability Date shall continue to be exercisable during the thirty-six (36) month period following the such date
    of death or Disability Date, as the case may be.

 

    	21

    	 

    

 

The
number of Options granted to a Participant in the year that includes the Participant’s date of death or Disability Date that remain
eligible to Vest following such date of death or Disability Date (the “Special
Pro Rated Options”) shall be determined by the formula A x B/C where:

 

	 	A	equals
    the total number of Options included in the Grant that have not previously Vested,
	 	 	 
	 	B	equals
    the total number of days between January 1 of the year that includes the Grant Date of such Grant and the Participant’s date
    of death or Disability Date, and
	 	 	 
	 	C	365.

 

The
Special Pro Rated Options shall continue to Vest and, upon Vesting, be exercisable during the thirty-six (36) month period following
the Participant’s date of death or Disability Date, as the case may be as if the Participant had remained Employed throughout such
period. The balance of the Options granted to a Participant in the year that includes the Participant’s date of death or Disability
Date that are not Special Pro Rated Options shall be forfeited and cancelled as of the Participant’s date of death or Disability
Date, as the case may be.

 

	 	11.3	Subject
    to the applicable Grant Agreement, Section 11.1 and Section 11.6, in the case of a Participant’s Termination due to the termination
    of the Participant’s employment or termination of the Participant’s contract for services by the Corporation or an Affiliate
    without Cause, (i) those of the Participant’s outstanding Options that have not become Vested prior to the Participant’s
    Termination shall continue to Vest and, upon Vesting, be exercisable during the one hundred and twenty (120) day period following
    the Participant’s Termination as if the Participant had remained Employed throughout such period, and (ii) those of the Participant’s
    outstanding Options that have become Vested prior to the Participant’s Termination shall continue to be exercisable during
    the one hundred and twenty (120) day period following the Participant’s Date of Termination.
	 	 	 
	 	11.4	Subject
    to the applicable Grant Agreement and Section 11.6, in the case of a Participant’s Termination due to the Participant’s
    resignation (including the voluntary withdrawal of services by a Participant who is not an employee under Applicable Law), (i) those
    of the Participant’s outstanding Options that have not become Vested prior to the date on which the Participant provides notice
    to the Corporation of his or her resignation shall be forfeited and cancelled as of such date, and (ii) those of the Participant’s
    outstanding Options that have become Vested prior to the date on which the Participant provides notice to the Corporation of his
    or her resignation shall continue to be exercisable during the ninety (90) day period following the Participant’s date of Termination.
	 	 	 
	 	11.5	Notwithstanding
    the foregoing, with respect to any Option that is intended to be an Incentive Stock Option, such Option shall not be exercisable
    for a period that is longer than (i) three (3) months from the date of the Participant’s Termination for any reason other than
    death or disability (as defined in Code Section 22(e)), or (ii) twelve (12) months from the Participant’s Termination due to
    disability (as defined in Code Section 22(e)) or death.

 

    	22

    	 

    

 

	 	11.6	In
    addition to the Board’s rights under Section 3.1, the Board may, at the time of a Participant’s Termination or Disability
    Date, extend the period for exercise of some or all of the Participant’s Options, but not beyond the original expiry date,
    and/or allow for the continued Vesting of some or all of the Participant’s Options during the period for exercise or a portion
    of it. Options that are not exercised prior to the expiration of the exercise period, including any extended exercise period authorized
    pursuant to this Section 11.6, following a Participant’s date of Termination or Disability Date, as the case may be, shall
    automatically expire on the last day of such period.
	 	 	 
	 	11.7	Notwithstanding
    any other provision hereof or in any Grant Agreement, in the case of a Participant’s termination of employment or termination
    of the Participant’s contract for services for Cause, any and all then outstanding unvested Options granted to the Participant
    shall be immediately forfeited and cancelled, without any consideration therefore, as of the commencement of the day that notice
    of such termination is given.
	 	 	 
	 	11.8	For
    greater certainty, a Participant shall have no right to receive Shares or a cash payment, as compensation, damages or otherwise,
    with respect to any Options that do not become Vested or that are not exercised before the date on which the Options expire.

 

	12.	Transferability
    of OPtions – us taxpayer

 

	 	12.1	Notwithstanding
    Section 7.11, with respect to Participants who are US Taxpayers, no Incentive Stock Option shall be transferable by the Participant,
    in whole or in part, other than by will or by the laws of descent and distribution. If the Participant shall attempt any transfer
    of any Incentive Stock Option, such transfer shall be void and the Incentive Stock Option shall terminate.
	 	 	 
	 	12.2	Further,
    with respect to Participants who are US Taxpayers, Options that are not Incentive Stock Options shall be transferable, in whole or
    in part, by the Participant by will or by the laws of descent and distribution. In addition, the Board may, in its sole discretion,
    permit the Participant to transfer any or all such Options to any member of the Participant’s “immediate family”
    as such term is defined in Rule 16a-1(e), or any successor provision, of the U.S. Securities Exchange Act of 1934, as amended, or
    to one or more trusts whose beneficiaries are members of such Participant’s “immediate family” or partnerships
    in which such family members are the only partners; provided, however, that the Participant cannot receive any consideration for
    the transfer and such transferred Stock Option shall continue to be subject to the same terms and conditions as were applicable to
    such Option immediately prior to its transfer.

 

PART
III – SHARE UNITS

 

	13.	DEFINITIONS

 

	 	13.1	“Grant
    Value” means the dollar amount allocated to an Eligible Person in respect of a Grant of Share
    Units as contemplated by Section 3.
	 	 	 
	 	13.2	“Share
    Unit Account” has the meaning set out in Section 15.1.

 

    	23

    	 

    

 

	 	13.3	“Valuation
    Date” means the date as of which the Market Value is determined for purposes of calculating
    the number of Share Units included in a Grant, which unless otherwise determined by the Board shall be the Grant Date.
	 	 	 
	 	13.4	“Vesting
    Period” means, with respect to a Grant of Share Units, the period specified by the Board,
    commencing on the Grant Date and ending on the last Vesting Date for such Share Units.

 

	14.	Eligibility
    and Grant Determination.

 

	 	14.1	The
    Board may from time to time make one or more Grants of Share Units to Eligible Persons on such terms and conditions, consistent with
    the Plan, as the Board shall determine, provided that, in determining the Eligible Persons to whom Grants are to be made and the
    Grant Value for each Grant, the Board shall take into account the terms of any written employment agreement or contract for services
    between an Eligible Person and the Corporation or any Affiliate and may take into account such other factors as it shall determine
    in its sole and absolute discretion.
	 	 	 
	 	14.2	The
    Board shall determine the Grant Value and the Valuation Date (if not the Grant Date) for each Grant under this Part III. The number
    of Share Units to be covered by each such Grant shall be determined by dividing the Grant Value for such Grant by the Market Value
    of a Share as at the Valuation Date for such Grant, rounded up to the next whole number.
	 	 	 
	 	14.3	Each
    Grant Agreement issued in respect of Share Units shall set forth, at a minimum, the type of Share Units and Grant Date of the Grant
    evidenced thereby, the number of RSUs or PSUs subject to such Grant, the applicable Vesting conditions, the applicable Vesting Period(s)
    and the treatment of the Grant upon Termination and may specify such other terms and conditions consistent with the terms of the
    Plan as the Board shall determine or as shall be required under any other provision of the Plan. The Board may include in a Grant
    Agreement under this Part III terms or conditions pertaining to confidentiality of information relating to the Corporation’s
    operations or businesses which must be complied with by a Participant including as a condition of the grant or Vesting of Share Units.

 

	15.	ACCOUNTS
    AND DIVIDEND EQUIVALENTS

 

	 	15.1	Share
    Unit Account.
	 	 	 
	 	 	An
    account, called a “Share Unit Account”, shall be maintained by the Corporation, or an Affiliate, as specified
    by the Board, for each Participant who has received a Grant of Share Units and will be credited with such Grants of Share Units as
    are received by a Participant from time to time pursuant to Section 14 and any dividend equivalent Share Units pursuant to Section
    15.2. Share Units that fail to Vest to a Participant and are forfeited pursuant to Section 16, or that are paid out to the Participant
    or his or her Beneficiary, shall be cancelled and shall cease to be recorded in the Participant’s Share Unit Account as of
    the date on which such Share Units are forfeited or cancelled under the Plan or are paid out, as the case may be. For greater certainty,
    where a Participant is granted both RSUs and PSUs, such RSUs and PSUs shall be recorded separately in the Participant’s Share
    Unit Account.

 

    	24

    	 

    

 

	 	15.2	Dividend
    Equivalent Share Units.
	 	 	 
	 	 	Except
    as otherwise provided in the Grant Agreement relating to a Grant of RSUs or PSUs, if and when cash dividends (other than extraordinary
    or special dividends) are paid with respect to Shares to shareholders of record as of a record date occurring during the period from
    the Grant Date under the Grant Agreement to the date of settlement of the RSUs or PSUs granted thereunder, a number of dividend equivalent
    RSUs or PSUs, as the case may be, shall be credited to the Share Unit of Account of the Participant who is a party to such Grant
    Agreement. The number of such additional RSUs or PSUs will be calculated by dividing the aggregate dividends or distributions that
    would have been paid to such Participant if the RSUs or PSUs in the Participant’s Share Unit Account had been Shares by the
    Market Value on the date on which the dividends or distributions were paid on the Shares. The additional RSUs or PSUs granted to
    a Participant will be subject to the same terms and conditions, including Vesting and settlement terms, as the corresponding RSUs
    or PSUs, as the case may be.

 

	16.	VESTING
    AND SETTLEMENT OF SHARE UNITS

 

	 	16.1	Continued
    Employment.
	 	 	 
	 	 	Subject
    to this Section 16 and the applicable Grant Agreement, Share Units subject to a Grant and dividend equivalent Share Units credited
    to the Participant’s Share Unit Account in respect of such Share Units shall Vest in such proportion(s) and on such Vesting
    Date(s) as may be specified in the Grant Agreement governing such Grant provided that the Participant is Employed on the relevant
    Vesting Date.
	 	 	 
	 	16.2	Settlement.
	 	 	 
	 	 	A
    Participant’s RSUs and PSUs, adjusted in accordance with the applicable multiplier, if any, as set out in the Grant Agreement,
    and rounded down to the nearest whole number of RSUs or PSUs, as the case may be, shall be settled, by a distribution as provided
    below to the Participant or his or her Beneficiary, upon, or as soon as reasonably practicable following the Vesting thereof in accordance
    with Section 16.1 or 16.6, as the case may be, subject to the terms of the applicable Grant Agreement. In all events RSUs and PSUs
    will be settled on or before the earlier of the ninetieth (90th) day following the Vesting Date and the date that is two
    and one half (21⁄2) months after the end of the year in which Vesting occurred. Settlement shall be made by the issuance of
    one Share for each RSU or PSU then being settled, a cash payment equal to the Market Value of the RSUs or PSUs being settled in cash,
    or a combination of Shares and cash, all as determined by the Board in its discretion, or as specified in the applicable Grant Agreement,
    and subject to payment or other satisfaction of all related withholding obligations in accordance with Section 7.2.
	 	 	 
	 	16.3	Postponed
    Settlement.
	 	 	 
	 	 	If
    a Participant’s Share Units would, in the absence of this Section 16.3 be settled within a Blackout Period applicable to such
    Participant, such settlement shall be postponed until the earlier of the sixth (6th) Trading Day following the end of
    such Blackout Period and the otherwise applicable date for settlement of the Participant’s Share Units as determined in accordance
    with Section 16.2.

 

    	25

    	 

    

 

	 	16.4	Failure
    to Vest.

 

	 	 	For
    greater certainty, a Participant shall have no right to receive Shares or a cash payment, as compensation, damages or otherwise,
    with respect to any RSUs or PSUs that do not become Vested.

 

	 	16.5	Resignation.

 

	 	 	Subject
    to the applicable Grant Agreement and Section 16.8, in the event a Participant’s employment is Terminated as a result of the
    Participant`s resignation, no Share Units that have not Vested prior to the date of on which the Participant submits his or her resignation,
    including dividend equivalent Share Units in respect of such Share Units, shall Vest and all such Share Units shall be forfeited
    immediately.

 

	 	16.6	Death
    or Disability.

 

	 	 	Subject
    to the applicable Grant Agreement, in the case of a Participant`s Termination due to death, or in the case of the Participant`s Disability,
    all Share Units granted to the Participant that were granted prior to the year that includes the Participant’s date of death
    or Disability Date, as the case may be, that have not Vested prior to the Participant`s date of death or Disability Date, as the
    case may be, and related dividend equivalent Share Units credited prior to such date of death or Disability Date, shall Vest at the
    end of the Vesting Period relating to such Grant(s) of such Share Units and in the case of a Grant of PSUs, subject to the achievement
    of the applicable Performance Conditions and the adjustment of the number of PSUs that Vest to reflect the extent to which such Performance
    Conditions were achieved, as if the Participant had remained Employed by the Corporation or an Affiliate until the end of the Vesting
    Period applicable to such Share Units.
	 	 	 
	 	 	The
    number of Share Units granted to a Participant in the year that includes the Participant’s date of death or Disability Date
    that remain eligible to Vest following such date of death or Disability Date (the “Special
    Pro Rated Share Units”) shall be determined by the formula A x B/C where:

 

	 	A	equals
    the total number of Share Units relating to such Grant that have not previously Vested,
	 	 	 
	 	B	equals
    the total number of days between January 1 of the year that includes the Grant Date of such Grant and the Participant’s date
    of death or Disability Date, and
	 	 	 
	 	C	365.

 

	 	 	The
    Special Pro Rated Share Units, together with any dividend equivalent Share Units attributable thereto, shall Vest at the end of the
    Vesting Period relating to such Grant(s) of such Share Units and in the case of a Grant of PSUs that are subject to Performance Conditions,
    subject to the achievement of the applicable Performance Conditions and the adjustment of the number of Special Pro Rated PSUs and
    related dividend equivalent PSUs that Vest to reflect the extent to which such Performance Conditions were achieved, as if the Participant
    had remained Employed by the Corporation or an Affiliate until the end of the Vesting Period applicable to such Share Units. The
    balance of the Share Units included in a Grant made in the year that includes the Participant’s date of death or Disability
    Date that are not Special Pro Rated Share Units shall be forfeited and cancelled as of the Participant’s date of death or Disability
    Date, as the case may be.

 

    	26

    	 

    

 

	 	16.7	Termination
    of Employment without Cause.

 

	 	 	Subject
    to the applicable Grant Agreement and Section 16.8, in the event a Participant’s employment or contract for services is terminated
    by the Corporation, or an Affiliate, as applicable, without Cause, prior to the end of a Vesting Period relating to a Grant:

 

	 	(a)	the
    number of RSUs determined by the formula A x B/C, where

 

	 	A	equals
    the total number of RSUs relating to such Grant that have not previously Vested and dividend equivalent RSUs in respect of such RSUs,
	 	 	 
	 	B	equals
    the total number of days between the first day of the Vesting Period relating to such Grant and the Participant’s date of Termination,
    and
	 	 	 
	 	C	equals
    total number of days in the Vesting Period relating to such Grant,
	 	 	 
	 	 	shall
    become Vested RSUs at the end of the Vesting Period relating to such Grant; and

 

	 	(b)	the
    number of PSUs (if any) determined by the formula A x B/C, where

 

	 	A	equals
    the total number of PSUs relating to such Grant that have not previously Vested and dividend equivalent PSUs in respect of such PSUs
    that would have Vested had the Participant remained Employed until the end of the applicable Vesting Period having regard to the
    extent to which the applicable Performance Conditions were satisfied,
	 	 	 
	 	B	equals
    the total number of days between the first day of the Performance Period relating to such Grant and the Participant’s date
    of Termination, and
	 	 	 
	 	C	equals
    total number of days in the Performance Period relating to such Grant,
	 	 	 
	 	 	shall
    become Vested PSUs at the end of Vesting Period relating to such Grant.

 

	 	16.8	Extension
    of Vesting.

 

	 	 	The
    Board may, at the time of Termination or a Disability Date, extend the period for Vesting of Share Units, but not beyond the original
    end of the applicable Vesting Period.

 

    	27

    	 

    

 

	 	16.9	Termination
    of Employment for Cause.

 

	 	 	In
    the event a Participant’s employment is Terminated for Cause by the Corporation, no Share Units, that have not Vested prior
    to the date of the Participant’s Termination for Cause including dividend equivalent Share Units in respect of such Share Units,
    shall Vest and all such Share Units shall be forfeited immediately.

 

	17.	SHAREHOLDER
    RIGHTS

 

	 	17.1	No
    Rights to Shares.

 

	 	 	Share
    Units are not Shares and a Grant of Share Units will not entitle a Participant to any shareholder rights, including, without limitation,
    voting rights, dividend entitlement or rights on liquidation.

 

PART
IV – RESTRICTED STOCK AND OTHER AWARDS

 

	18.	DEFINITIONS

 

	 	18.1	“Restriction”
    means any restriction on a Participant’s free enjoyment of the Shares granted as Restricted Stock. Restrictions may be based
    on the passage of time or the satisfaction of Performance Conditions or the occurrence of one or more events or conditions, and shall
    lapse separately or in combination upon satisfaction of such conditions and at such time or times, in instalments or otherwise, as
    the Board shall specify.

 

	19.	Restricted
    Stock

 

	 	19.1	Dividends;
    Voting.
	 	 	 
	 	 	While
    any Restriction applies to any Participant’s Restricted Stock, (i) unless the Board provides otherwise, the Participant shall
    receive the dividends paid on the Restricted Stock and shall not be required to return those dividends to the Corporation in the
    event of the forfeiture of the Restricted Stock, (ii) the Participant shall receive the proceeds of the Restricted Stock in the event
    of any change in the Shares in respect of which the Board has determined that an equitable adjustment should be made pursuant to
    Section 5.1, which proceeds shall automatically and without need for any other action become Restricted Stock and be subject to all
    Restrictions then existing as to the Participant’s Restricted Stock, and (iii) the Participant shall be entitled to vote the
    Restricted Stock during the Restriction period.
	 	 	 
	 	19.2	Transfer
    Restrictions.
	 	 	 
	 	 	The
    Participant shall not have the right to sell, transfer, assign, convey, pledge, hypothecate, grant any security interest in or mortgage
    on, or otherwise dispose of or encumber any shares of Restricted Stock or any interest therein while the Restrictions remain in effect.
    The Board may require, as a condition of a Grant of Restricted Stock, that the Participant deposit the shares of Restricted Stock
    into an escrow account.

 

    	28

    	 

    

 

	 	19.3	Forfeiture.
	 	 	 
	 	 	Grants
    of Restricted Stock shall be forfeited if the applicable Restriction does not lapse prior to such date or the occurrence of such
    event or the satisfaction of such other criteria as is specified in the Grant Agreement. Further, unless expressly provided for in
    the Grant Agreement, or as otherwise determined by the Board, any Restricted Stock held by the Participant at the time of the Participant’s
    Termination shall be forfeited by the Participant to the Corporation.
	 	 	 
	 	19.4	Evidence
    of Share Ownership.
	 	 	 
	 	 	Restricted
    Stock will be book-entry Shares only unless the Board decides to issue certificates to evidence shares of the Restricted Stock.

 

	20.	OTHER
    AWARDS

 

The Board shall have the authority to grant other equity-based awards, which may be based on one or more criteria determined by
the Board, under the Plan that are consistent with the purpose of the Plan and the interests of the Corporation, including, without limitation,
bonuses or similar compensation payable in the form of Shares, subject to compliance with Applicable Law.

 

    	29

    	 

    

 

Exhibit
“A”

 

to

 

VBI
Vaccines Inc. Incentive Plan

 

Special
Provisions Applicable to US Taxpayer

 

This
Exhibit sets forth special provisions of the VBI Vaccines Inc. Incentive Plan (the “Plan”) that apply to Participants who
are US Taxpayers. This Exhibit shall apply to such Participants notwithstanding any other provisions of the Plan. Terms defined elsewhere
in the Plan and used herein shall have the meanings set forth in the Plan, as may be amended from time to time.

 

Definitions

 

“Disability”
means, solely with respect to an award that constitutes deferred compensation subject to Section 409A of the Code, a “disability”
as defined under Section 409A of the Code.

 

“Eligible
Person” means, solely with respect to Options and SARs, an individual Employed by the Corporation or any of its subsidiaries
who, by the nature of his or her position or job is, in the opinion of the Board, in a position to contribute to the success of the Corporation;
provided, however, that only officers and employees shall be eligible to receive Incentive Stock Options.

 

“Market
Price” means, solely with respect to the terms “Exercise Price” and “Base Price”, (a) if the Shares
are listed on the Stock Exchange, the closing price per Share on the Stock Exchange on the Effective Date of the Grant; (b) if the Shares
are listed on more than on Stock Exchange, the fair market value as determined in accordance with paragraph (a) above for the primary
Stock Exchange on which the Shares are listed, as determined by the Board; and (c) if the Shares not listed for trading on a Stock Exchange,
a price which is determined by the Board in good faith to be the fair market value of the Shares in compliance with the Code Section
409A.

 

“Separation
From Service” means such employment or service with the Corporation and any entity that is to be treated as a single employer
with the Corporation for purposes of United States Treasury Regulation Section 1.409A-1(h) terminates such that it is reasonably anticipated
that no further services will be performed.

 

“Specified
Employee” means a US Taxpayer who meets the definition of “specified employee,” as defined in Section 409A(a)(2)(B)(i)
of the Code.

 

Change
in Control Treatment

 

Notwithstanding
anything to the contrary, if the Change in Control event does not constitute a change in ownership or effective control of the Company
or a change in ownership of a substantial portion of the assets of the Company under Section 409A of the Code, and if the Corporation
determines any award under the Plan constitutes deferred compensation subject to Section 409A of the Code, then as determined in the
sole discretion of the Board, the vesting of such award may be accelerated as of the effective date of the Change in Control, but the
Corporation shall pay such award on its original payment date, but in no event more than 90 days following the original payment date.

 

Compliance
with Section 409A

 

The
intent of the parties is that payments and benefits under this Plan comply with Section 409A of the Code, to the extent subject thereto,
and accordingly, to the maximum extent permitted, this Plan shall be interpreted and administered to be in compliance therewith. Notwithstanding
anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and/or tax penalties under Section
409A of the Code, a Participant shall not be considered to have terminated employment with the Company for purposes of this Plan unless
the Participant would be considered to have incurred a Separation From Service from the Company. Each amount to be paid or benefit to
be provided under this Plan shall be construed as a separate identified payment for purposes of Section 409A of the Code, and any payments
described in this Plan that are due within the “short term deferral period” as defined in Section 409A of the Code shall
not be treated as deferred compensation unless applicable law requires otherwise. Without limiting the foregoing and notwithstanding
anything contained herein to the contrary, to the extent required in order to avoid accelerated taxation and/or tax penalties under Section
409A of the Code, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to this Plan (or any
other plan or agreement of the Corporation) during the six-month period immediately following the Specified Employee’s Separation
From Service shall instead be paid on the first business day after the date that is six months following the Specified Employee’s
Separation From Service (or death, if earlier). The Plan and any award agreements issued thereunder may be amended in any respect deemed
by the Board to be necessary in order to preserve compliance with Section 409A of the Code. The Corporation makes no representation that
any or all of the payments described in this Plan will be exempt from or comply with Section 409A of the Code and makes no undertaking
to preclude Section 409A of the Code from applying to any such payment. Each Participant shall be solely responsible for the payment
of any taxes and penalties incurred under Section 409A of the Code.

 

    	30

    	 

    

 

Exhibit
“B”

 

to

 

VBI
Vaccines Inc. Incentive Plan

 

Addendum
Applicable to Israeli Taxpayer

 

	1.	Purpose
  of the Addendum: This Israeli Addendum (the “Addendum”) shall form an integral part of the VBI Vaccines Inc.
  Incentive Plan (the “Plan”), and it shall apply only to Participants who are deemed residents of the State of Israel
  for the purpose of Israeli tax laws and are employed or engaged by the Corporation’s Israeli resident subsidiary (“Israeli
  Participants”).

 

This
Addendum supplements the Plan so that it shall comply with the requirements of the Israeli Tax Ordinance (as defined below).

 

The
Plan and this Israeli Addendum are complimentary to each other and shall be read and deemed as one. Any requirements provided in this
Addendum shall be in addition to the requirements provided in the Plan and in the Grant Agreement. In the event of conflict, whether
explicit or implied, between the provisions of the Plan and this Addendum, the latter shall govern and prevail with respect to Grants
to Israeli Participants.

 

	2.	Definitions:

 

Unless
otherwise defined herein, the terms defined in this Addendum shall have the same meaning as set out in the Plan.

 

For
the purposes of this Addendum, the following terms shall have the meaning set forth below:

 

	 	(a)	“Additional
    Rights” means any distribution of rights, including an issuance of bonus shares granted in accordance with the terms of
    the Plan, in connection with Section 102 Trustee Grants (as defined below) and/or with the Shares issued thereunder.
	 	 	 
	 	(b)	“Affiliate(s)”
    Without derogating from the definition of Affiliate(s) in the Plan and solely with respect to to Section 102 Trustee Grants (as defined
    below), “Affiliate(s)” means an “employing company” within the meaning of Section 102(a) of the Tax Ordinance.
	 	 	 
	 	(c)	“Controlling
    Shareholder” shall have the same meaning ascribed to it in Section 32(9) of the Tax Ordinance.
	 	 	 
	 	(d)	“Employee”
    shall mean, solely with respect to to Section 102 Trustee Grants and Section 102 Non-Trustee Grants (as defined below), any Eligble
    Person who is an Israeli Participant, and office holders of the Company’s Israeli resident subsidiary (“Nosei Misra”
    as such term is defined in the Israeli Companies Law), but exclude any person who is a Controlling Shareholder of the Corporation
    prior to or after the Grants.

 

    	31

    	 

    

 

	 	(e)	“Fair
    Market Value” means, for the purpose of determining the tax liability with respect to the grant of Capital Gain Grant Through
    a Trustee pursuant to Section 102(b)(3), if applicable; (i) if at the date of grant the Corporation’s stock is listed on any
    established stock exchange or a national market system or if the Corporation’s stock will be registered for trading within
    ninety (90) days following the date of grant, the Fair Market Value of a Share at the date of grant shall be determined in accordance
    with the average value of the Shares on the thirty (30) trading days preceding the date of grant or on the thirty (30) trading days
    following the date of registration for trading, as the case may be; (ii) if the stock is regularly quoted by a recognized securities
    dealer but selling prices are not reported, the Fair Market Value shall be the mean between the high bid and low asked prices for
    the Shares on the last market trading day prior to the day of determination.
	 	 	 
	 	(f)	“ITA”
    means the Israeli Income Tax Authorities.
	 	 	 
	 	(g)	“Lock-up
    Period” means the period during which the Section 102 Trustee Grants made to an Israeli Participant or, the Shares underlying
    the Section 102 Trustee Grants, as well as any Additional Rights issued or distributed in connection therewith are to be held by
    the Trustee (as defined below) on behalf of the Israeli Participant, in accordance with Section 102 pursuant to the tax route which
    the Corporation elects.
	 	 	 
	 	(h)	“Section
    102” means Section 102 of the Israeli Income Tax Ordinance, and any regulations, rules, orders or procedures promulgated
    thereunder, all as amended, and the Rules.
	 	 	 
	 	(i)	“Non-Employee”
    means any Israeli Participant who is not an Employee.
	 	 	 
	 	(j)	“Rules”
    means the Income Tax Rules (Tax Relief upon the Allotment of Shares to Employees), 2003, and any regulations, rules, orders or procedures
    promulgated thereunder, all as amended.
	 	 	 
	 	(k)	“Section
    3(i)” means Section 3(i) of the Tax Ordinance, and any regulations, rules, orders or procedures promulgated thereunder,
    all as amended.
	 	 	 
	 	(l)	“Section
    3(i) Grant” means a Grant made to Israeli Participant pursuant to Section 3(i).
	 	 	 
	 	(m)	“Section
    102 Trustee Grant” means a Grant of Options and/or RSU made to Israeli Participant that by its terms qualifies and is intended
    to qualify under the provisions of Section 102(b) of the Tax Ordinance (including the Section 102(b) Route Election (as defined below)),
    as either:

 

	 	1)	“Ordinary
    Income Grant Through a Trustee” for the special tax treatment under Section 102(b)(1) and the “Ordinary Income Route”,
    or
	 	 	 
	 	2)	“Capital
    Gain Grant Through a Trustee” for the special tax treatment under Section 102(b)(2) or Section 102(b)(3) and the “Capital
    Route”.

 

	 	(n)	“Section
    102(b) Route Election” means the right of the Corporation to choose either the “Capital Route” (as set under
    Section 102(b)(2)), or the “Ordinary Income Route” (as set under Section 102(b)(1)), subject to the provisions of Section
    102(g) of the Tax Ordinance.
	 	 	 
	 	(o)	“Section
    102 Non-Trustee Grant” means a Grant made not through a trustee under the terms of Section 102(c) of the Tax Ordinance.

 

    	32

    	 

    

 

	 	(p)	“Tax
    Ordinance” means the Israeli Income Tax Ordinance, 1961.
	 	 	 
	 	(q)	“Tax
    Ruling” shall mean any ruling or authorization which the Corporation or the Corporation’s Israeli resident subsidiary,
    at its sole and absolute discretion, may obtain from the ITA in connection with the Plan or the Grants made thereunder, including
    any terms and conditions and restrictions set forth therein.
	 	 	 
	 	(r)	“Trustee”
    means a person or an entity, appointed by the Board and approved in accordance with the provisions of Section 102, to hold in trust
    on behalf of the Employees the Section 102 Trustee Grants, or the Shares issued thereunder, as well as all Additional Rights granted
    in connection therewith, in accordance with the provisions of Section 102.
	 	 	 
	 	(s)	“Trust
    Agreement” means a written agreement between the Corporation or any Affiliate and the Trustee, which sets forth the terms
    and conditions of the trust and is in accordance with the provisions of Section 102.

 

	3.	Administration:
    Further to the authorities of the Board, as detailed in the Plan, with regard to this Addendum, the Board shall have full power and
    authority to: (i) designate Grants made under this Addendum as either a Section 102 Trustee Grant, Section 102 Non-Trustee Grant
    or Section 3(i) Grant; (ii) make a Section 102(b) Route Election; (iii) adapt the forms of Grant Agreements to include provisions
    regarding Grants in accordance with this Addendum and any applicable law; and (iii) determine any other matter and execute any document
    which are necessary or desirable for, or incidental to, the administration of the Addendum and the Grants made hereunder and the
    issuance and delivery of any underlying Shares, including without limitation the appointment of a Trustee, the execution of a Trust
    Agreement and any other document necessary for submission of the Plan and this Addendum to the ITA, including, if so decided by the
    Corporation at its sole discretion, the filing of a Tax Ruling.
	 	 
	4.	Eligibility:

 

4.1
Subject to the terms and conditions of the Plan, Section 102 Trustee Grants and Section 102 Non-Trustee Grants may only be made to Employees.
Section 3(i) Grants may be made only to Non-Employees.

 

4.2
Subject to the terms and conditions of the Plan, Grants made under this Addendum to Israeli Participants may only consist of Options
and/or RSU.

 

4.3
Grants made under this Addendum to Israeli Participants who are Employees are intended to qualify as Section 102 Trustee Grants.

 

	5.	Section
    102(b) Route Election: No Section 102 Trustee Grant may be made under this Addendum, unless and until, the Corporation’s
    election of the type of Section 102 Trustee Grants, either as “Ordinary Income Grant Through a Trustee” or as “Capital
    Gain Grant Through a Trustee”, is appropriately filed with the Income Tax Authorities before the first date of grant of Section
    102 Trustee Grant. The Section 102(b) Route Election shall obligate the Corporation in accordance with the provisions of Section
    102(g) of the Tax Ordinance. For avoidance of doubt, it is clarified that the Corporation does not obligate itself to file a Section
    102(b) Route Election, and in any case, such Section 102(b) Route Election shall be at the sole discretion of the Corporation. It
    is further clarified that such Section 102(b) Route Election shall not prevent the Corporation from granting Section 102 Non-Trustee
    Grants simultaneously.

 

    	33

    	 

    

 

	6.	Trustee:

 

6.1
Section 102 Trustee Grant, which shall be made under the Addendum and any Shares issued upon exercise or vesting thereof shall be issued
to and in the name of the Trustee who shall hold the same in trust for the benefit of the Employees at least for the applicable Lock-up
Period. Upon the expiration of the Lock-up Period and subject to any further period included in the Plan and/or in the Grant Agreement,
the Trustee may release Section 102 Trustee Grant or Shares issued upon exercise or vesting thereof only after the Employee’s full
payment of his or her tax liability in connection therewith due pursuant to the Tax Ordinance and the Rules and any applicable Tax Ruling.

 

6.2
Notwithstanding the above, in the event that an Employee shall elect to release Section 102 Trustee Grants or the Shares issued thereunder
prior to the expiration of the Lock-up Period, the sanctions under Section 102 shall apply to and shall be borne solely by the Employee.

 

6.2
Any Additional Rights distributed to Employees shall be deposited with and/or issued to the Trustee for the benefit of the Employees,
and shall be held by the Trustee for the applicable Lock-up Period in accordance with the provisions of Section 102 and the Rules and
any applicable Tax Ruling.

 

6.3
As a condition to any Grant of Section 102 Trustee Grant, the Israeli Participants shall provide the Corporation and the Trustee with
a written undertaking and confirmation under which each Israeli Participant confirms that he/she is aware of the provisions of Section
102 and the applicable Section 102(b) Route Election and agrees to the provisions of the Trust Agreement (including the ancillary trust
note thereto) between the Corporation and the Trustee and agrees to comply with the Tax Ordinance, the Rules and the provisions of the
Trust Agreement and any applicable Tax Ruling, and undertakes not to release, by sale or transfer, the Section 102 Trustee Grant, and
the Shares issued thereunder, and all rights attached thereto (including Additional Rights) prior to the lapse of the applicable Lock-up
Period. The Israeli Participants shall not be entitled to sell or release from trust the Section 102 Trustee Grant, nor the Shares issued
thereunder, nor any right attached thereto (including Additional Rights), nor to request the transfer or sale of any of the same to any
third party, before the lapse of the Lock-up Period. The Israeli Participants shall further agree to exempt the Trustee from any liability
in respect of any action or decision duly taken and bona fide executed in relation with the Plan, the Addendum and any Grant,
Shares or other rights received in connection therewith.

 

6.4
For as long as the Trustee holds Shares in trust for the benefit of the Employees, the Trustee shall not use the voting rights vested
in such Shares, and shall not exercise such rights in any way whatsoever. In the event the right to vote such Shares is held by the Trustee
pursuant to Section 102, then upon the exercise of any Option the Trustee shall execute a voting proxy in such form as may be prescribed
by the Board, subject to the provisions of Section 102.

 

	7.	The
    Corporation may make Section 102 Trustee Grants only after the passage of thirty (30) days’ following the delivery, to the
    appropriate Israeli Income Tax Authorities, of a request for approval of the Plan and the Addendum as well as the Trustee according
    to Section 102, or after a shorter period, if approved by the Israeli Income Tax Authorities. Notwithstanding the above, if within
    ninety (90) days’ following the delivery of such request, the tax officer notifies the Corporation of its decision not to approve
    the Plan and/or the Addendum, the Grants, which were intended to be made as Section 102 Trustee Grants, shall be deemed to be Section
    102 Non-Trustee Grants, unless otherwise was approved by the tax officer.
	 	 
	8.	Tax
    Consequences: Any tax consequences arising from the grant or exercise of a Grant, from the issuance or sale of Shares covered
    thereby or from any other event or act (of the Israeli Participant, the Corporation, its Affiliate or the Trustee) hereunder, shall
    be borne solely by the Israeli Participant. The Corporation and/or its Affiliates and/or the Trustee shall withhold all applicable
    taxes according to the requirements under the Tax Ordinance, the Rules, any applicable Tax Ruling and any other applicable laws,
    rules, and regulations, including withholding taxes at source. The Corporation and/or the Trustee shall not be required to release
    any Grants or issue or transfer any underlying Shares until all required payments have been fully made.

 

8.1
The Corporation may require, as a condition to any Grants or the issuance or delivery of underlying Shares, that an Israeli Participant
provide a security or guarantee to the satisfaction of the Corporation, to secure payment of all taxes which may become due upon the
future transfer of his/her Shares to be issued under any Section 3(i) Grants.

 

    	34

    	 

    

 

8.2
Furthermore, the Employee shall agree to indemnify the Corporation and/or its Affiliates and/or the Trustee and hold them harmless against
and from any and all liability for any such tax or interest or penalty thereon, including without limitation, liabilities relating to
the necessity to withhold, or to have withheld, any such tax from any Grants or underlying Shares issued to the Israeli Participant thereunder.

 

8.3
In the event that an Employee shall cease to be employed by the Corporation or its Affiliate for any reason, the Employee shall be obligated,
upon the Corporation’s, the Affiliate’s or the Trustee’s first demand to provide the Corporation, its Affiliate and
the Trustee with a security or guarantee, in the degree and manner satisfactory to them, to cover any future tax obligation resulting
from the disposition of the Grants and/or the Shares acquired thereunder.

 

8.4
To the extent that Section 102 and/or the tax officer’s approval and/or any Tax Ruling require the Plan and/or this Addendum and/
or the Grant Agreement to contain specified provisions in order to qualify the Grants for the tax treatment under Section 102, such provisions
shall be deemed to be stated herein and/or in the Grant Agreement, as applicable, and to be binding upon the Corporation, any Affiliate
and the Israeli Participant.

 

8.5
The provisions in the Plan (i) relating to Preformance Conditions; and (ii) in Section 6.1(a) and 6.1(c) of the Plan, shall not apply
to Grants made under this Addendum.

 

	9.	Currency
    Exchange Rates: Except as otherwise determined by the Board, all monetary values with respect to Grants granted pursuant to this
    Addendum, including without limitation the Fair Market Value and the Exercise Price of any Option, shall be stated in United States
    Dollars. In the event that the exercise price is in fact to be paid in New Israeli Shekels, at the sole discretion of the Board,
    the conversion rate shall be the last known representative rate of the United States Dollar to the New Israeli Shekels on the date
    of payment.
	 	 
	10.	 Subordination
    to the Ordinance: The Grants, the Plan, this Addendum and any applicable Grant Agreements are subject to the applicable provisions
    of the Ordinance, which shall be deemed an integral part of each, and which shall prevail over any term that is inconsistent therewith.
	 	 
	11.	Additional
    Documents: Israeli Participants may be required to execute, in addition to the Grant Agreement, any and all other documents required
    by the Corporation or any Affiliate, (including without limitation any customary documents and undertakings towards the Trustee,
    if applicable, and/or any tax authorities). Notwithstanding anything to the contrary in the Plan or in this Addendum, no Grant shall
    be deemed made unless all documents required by the Corporation or any Affiliate to be signed by the Israeli Participant prior to
    or upon such Grant, shall have been duly signed and delivered to the Corporation or such Affiliate.
	 	 
	12.	Non-Transferability:
    Notwithstanding anything in the Plan to the contrary, with regard to Section 102 Trustee Grants and the Shares issued thereunder,
    as long as such Grants and/or Shares are held by the Trustee on behalf of the Employee, all rights of the Employee with respect thereto
    are personal and cannot be transferred, assigned, pledged or mortgaged, other than by will or by the laws of descent and distribution.
	 	 
	13.	Governing
    Law: Solely for tax purposes, this Addendum and all instruments issued thereunder or in connection therewith shall be governed
    by and construed and enforced in accordance with the applicable laws of the state of Israel, without giving effect to the principles
    of conflict of laws.

 

    	35[***]
Certain information has been excluded pursuant to Regulation S-K, Item 601(b)(10)(iv) from this Document because it is both not material
and is the type that the registrant treats as private or confidential.

 

Exhibit 10.21

 

 

 

Business
Confidential – Protected B

 

Non-Exclusive
Licence Included ☑

Exclusive Licence Included ☑

 

	BETWEEN:	NATIONAL
    RESEARCH COUNCIL OF CANADA
	 	a
    departmental corporation of the Government of Canada whose
    head office address is:
	 	1200
    Montreal Road
	 	Ottawa,
    Ontario K1A 0R6	(called
    the “NRC”)
	 	 	 
	AND:	VARIATION
    BIOTECHNOLOGIES INC.
	 	 
	 	A
    company incorporated under the Canada Business Corporations Act under number 393728-3 whose Registered Office
    Address is located in:
	 	310
    Hunt Club Road East, 2nd Floor
	 	Ottawa,
    Ontario   K1V 1C1	(called
the “Collaborator” or “VBI”)
	 	 	 
	 	 	(Collectively
    known as the “Parties”)

 

In
consideration of the mutual covenants hereunder, the Parties agree as follows:

 

	1.	This
    Agreement concerns scientific research and development, called the “Project”, described as: COVID-19 vaccine
    evaluation.
	 	 
	2.	The
    Collaborator chooses to work with the NRC because of the NRC’s unique capabilities, and does not expect the NRC to perform
    work that would be in competition with Canadian firms. Except as otherwise specified in this Agreement, the name of the NRC,
    or any reference to the NRC, shall not be used in promotional activities of the Collaborator without the NRC’s prior
    written consent.
	 	 
	3.	The
    Parties will contribute to the Project by the performance of work as described in the attached “Statement of Work and
    Deliverables”, or by payments, or both. This Agreement is subject to the terms in the attached “General Conditions”.
	 	 
	4.	The
    total value of the Project is estimated to be minimum of $[***] (no
    option) to a maximum of $[***] (with option).
	 	 
	5.	The
    Collaborator is a Canadian Small and Medium Enterprise (SME), and benefits from a Fee Reduction of minimum
    of $[***] (no option) to a maximum of $[***] (with option). The Customer hereby warrants that, at the time of signing
    this Agreement, it is a SME with 500 or fewer full-time equivalent employees, or it is a Canadian educational institution.
	 	 
	6.	The
    Collaborator shall pay to the NRC in cash the sum of minimum of $[***]
    (no option) to a maximum of $[***] (with option) according to the attached “Schedule of Payments”. The
    Collaborator shall also pay applicable sales taxes.

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 1 of 14

    	 

    

 

 

	7.	The
    Collaborator has initiated work to design monovalent & multivalent coronavirus constructs, at its own costs, using their
    eVLP platform and will include, in its constructs, up to 4 protein antigens provided by NRC.
	 	 
	8.	The
    NRC shall make a co-investment to the Project by performing, at its own cost, work described in the Statement of Work and
    Deliverables at an estimated value of $[***].
	 	 
	9.	This
    Agreement shall become effective when the last Party has signed
    and expires on 15 November 2020, except for the following terms
    and conditions which shall survive the termination or expiration of this Agreement:
	 	 	 
	 	(a)	payment
    obligations which accrued while this Agreement was in force, or upon its termination, and the interest provisions of this
    Agreement; and
	 	 	 
	 	(b)	the
    terms and conditions with respect to Intellectual Property which are found in the attached Annex IU
    entitled “Intellectual Property” that forms part of this Agreement; and
	 	 	 
	 	(c)	terms
    and conditions with respect to exclusion of certain liability, limited warranties, and dispute resolution, all of which are
    found in the attached General Conditions that form part of this Agreement.
	 	 	 
	10.	This
    Agreement shall be interpreted according to the laws of the Province of Ontario and the laws of Canada in force there. Subject
    to section GC-15, for any litigation concerning this Agreement, including litigation arising from arbitration, the Parties
    hereby irrevocably and unconditionally attorn to the exclusive jurisdiction of the Courts of the Province of Ontario, and
    all courts competent to hear appeals therefrom. The Parties expressly exclude any conflict of laws rules or principles that
    might refer disputes under this Agreement to the laws of another jurisdiction.
	 	 	 
	11.	This
    Agreement may be executed in one or more counterparts and by the different parties hereto in separate counterparts, each of
    which when executed shall be deemed to be an original but all of which taken together shall constitute one valid and binding
    Agreement. A portable document format (PDF) copy of an executed counterpart signature page will be as valid as an originally
    executed counterpart for purposes of signing this Agreement. 

 

	SIGNED by the Collaborator	 	 
	 	 	 
		 	VARIATION
    BIOTECHNOLOGIES INC.
	 	 	 	 	 
	Date:	March
    30, 2020	 	Per:	/s/
    Jeff Baxter
	 	 	 	 	Jeff
    Baxter
	 	 	 	 	CEO
	 	 	 	 	 
	SIGNED by the NRC at Ottawa,
    Ontario	 	 	 
	 	 	 	 	 
		 	NATIONAL
    RESEARCH COUNCIL OF CANADA
	 	 	 	 	 
	Date:	March
    30, 2020	 	Per:	/s/
    Lakshmi Krishnan
	 	 	 	 	Lakshmi
    Krishnan, Ph.D.
	 	 	 	 	Human
    Health Therapeutics

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 2 of 14

    	 

    

 

 

ANNEX
SP – SCHEDULE OF PAYMENTS TO THE NRC

 

Billing
address: See page 1

 

Billing
contact:

 

	Name:	Andrea
    McCrae
	Title:
    	Project
    Manager
	Telephone:	613
    749 4200
	Email:	amccrae@vbivaccines.com

 

	SP-1	The
                                         Collaborator shall be invoiced as follows:

 

	Schedule
    of Payments:  
	Work
    Task	 	Proposed
    Schedule of Payments	 	Task
    Value	 	NRC
    Co-investment	 	CAN
    SME Fee Reduction	 	NRC
    Pricing*	 	Final
    Price

    Amount Due*
	Task
    1: Assay development	 	 	 	[***]	 	[***]	 	 	 	 	 	 
	Task
    2: Immunogenicity in vivo	 	Invoiced
    upon completion of task	 	[***]	 	 	 	[***]	 	[***]	 	[***]
	Task
    3: PRNT assay	 	Invoiced
    upon completion of task	 	[***]	 	 	 	[***]	 	[***]	 	[***]
	Task
    4: Reporter assay	 	Invoiced
    upon completion of task	 	[***]	 	 	 	[***]	 	[***]	 	[***]
	Total
    Minimum (without options)*	 	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]
	 
	Total
    Maximum (with options)*	 	 	 	[***]	 	[***]	 	[***]	 	[***]	 	[***]

 

*
Plus applicable taxes

 

	SP-2	All
    amounts shall be due 30 days from the date of the invoice.
	 	 
	SP-3	Payments
    must be made to: “Receiver General - National Research Council of Canada” and addressed to:

 

Accounts
Receivable

National
Research Council of Canada

1200
Montreal Road

Ottawa,
Ontario, K1A 0R6

CANADA

 

	SP-4	Payments
    can be made by cheque; MasterCard, Visa or American Express; or by wire transfer. Wire transfer information is available upon
    request. The Collaborator is responsible for all bank charges associated with wire transfers. Any inquiries may be directed
    to: AccountsReceivable@nrc-cnrc.gc.ca.
	 	 
	SP-5	The
    Collaborator shall provide any Invoicing Reference Number at the time of Agreement signature or promptly thereafter. The NRC
    will not delay or cancel invoicing nor defer accrual of interest due to the Collaborator’s failure to provide an Invoicing
    Reference Number. 
	 	 
	SP-6	The
    NRC may suspend its performance of any obligations under this Agreement so long as any payment is overdue for any reason.
	 	 
	SP-7	If
    this Agreement is amended to increase the scope of the Project, the NRC reserves the right to calculate costing for its additional
    Project activities at its rates that are in effect at that time. Any such cost increases shall be approved, in writing, by
    both Parties.

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 3 of 14

    	 

    

 

 

	SP-8	If
    a Party expects that the value of its estimated contribution will be exceeded by
    more than 10%, it shall promptly notify the other Party. The Parties shall then negotiate a further agreement
    on costs or payments, and either Party may suspend the performance of any obligations, other than confidentiality, intellectual
    property and accrued obligations to pay, until a further agreement is reached. If the Parties fail to agree on an amendment
    within 60 days of the notice, then this Agreement shall terminate on the 60th day after the notice, unless the
    Parties agree otherwise in writing.
	 	 
	SP-9	If
    a surplus of prepayment remains as a result of premature termination, it will be refunded.
	 	 
	SP-10	If
    an instrument tendered in payment or settlement of an amount due to the NRC is dishonoured for any reason, the NRC will invoice
    an additional administrative charge of CAD 25 and this amount will be due as invoiced. 
	 	 
	SP-11	Interest
    is payable on all overdue amounts. Interest is calculated and compounded monthly at the average bank rate plus 3% and accrues
    during the period beginning on the due date and ending on the day before the day on which payment is received by the NRC.
    For purposes of this paragraph “bank rate” means the rate of interest established periodically by the Bank
    of Canada as the minimum rate at which the Bank of Canada makes short term advances to members of the Canadian Payments Association,
    and “average bank rate” means the weighted arithmetic average of the bank rates that are established during
    the month before the month in respect of which interest is being calculated.
	 	 
	 	(Rate
    information may be found at http://www.tpsgc-pwgsc.gc.ca/recgen/txt/tipp-ppir-eng.html. This site provides information
    on the rate used by departments of the Government of Canada to calculate the interest on overdue accounts payable and is the
    same rate used by the NRC to charge interest on overdue accounts receivable under the Interest and Administrative Charges
    Regulations, SOR/96-188. This web site address, and the information set out there, is provided here for convenience. In case
    of rate discrepancy, the rates quoted by the Bank of Canada shall prevail.)

 

(the
rest of this page was intentionally left blank)

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 4 of 14

    	 

    

 

 

ANNEX
GC: GENERAL CONDITIONS

 

	GC-1	INTERPRETATION
    OF AGREEMENT: This Agreement supersedes all prior communications, negotiations and agreements concerning the Project.
    Notwithstanding any language in a purchase order that is sent to the NRC by the Collaborator in respect of the Project, the
    purchase order is for administrative purposes only of the Collaborator and does not constitute an offer, a counter-offer,
    or an amendment to this Agreement nor does it create a new agreement in respect of the Project. The NRC shall include on the
    face of its invoice for the Project any purchase order number issued by the Collaborator for the Project.  No amendment
    or waiver of terms in this Agreement, including the annexes thereto, is effective unless it is in writing, signed by all Parties,
    except that the Parties agree that the Agreement may be extended by an exchange of email from their authorized representatives.
    In case of inconsistency between the STATEMENT OF WORK AND DELIVERABLES and the rest of this Agreement, the rest of this Agreement
    prevails. No forbearance by a Party implies any broader, continuing, or future forbearance. If a court finds part of this
    Agreement invalid, the remainder is valid in accordance with its most reasonable interpretation. This Agreement does not create
    a relationship of agency, employment, partnership, or joint venture.
	 	 
	GC-2	ASSIGNMENT:
    This Agreement, and any licence granted pursuant to it, is personal to the Parties, so that neither its assignment, nor
    its assumption by a corporation formed by amalgamation of a Party with a third party, is valid except by written consent of
    all Parties, which consent shall not be unreasonably withheld.
	 	 
	GC-3	EXCLUSION
    OF CERTAIN LIABILITY: No Party shall be liable for failure or delay in performance caused by circumstances beyond
    its reasonable control, or for incorrectness or inaccuracy of data supplied, advice given, or opinions expressed unless directly
    attributable to gross negligence or willful misconduct. No claim may be made for indirect, consequential, or incidental damages.
    No claim shall exceed the cost of the Project.
	 	 
	GC-4	LIMITED
    WARRANTIES: Each Party warrants that it will conduct the Project work in a professional manner conforming to generally
    accepted practices for scientific research and development. However, because of the nature of such work, no specific result
    is promised.
	 	 	 
	 	(a)	No
    Party warrants that technical information conveyed in the deliverables does not infringe the rights of third parties under
    a present or future patent.
	 	 	 
	 	(b)	No
    Party warrants the validity of patents under which rights may be granted pursuant to this Agreement, or makes any representation
    as to the scope of patents or that those inventions may be exploited without infringing the rights of others.
	 	 	 
	GC-5	TERMINATION
    OF AGREEMENT FOR COST OVERRUNS: If following notification by one Party that costs expressed as estimates will be exceeded
    by more than 10%, if the Parties do not amend this Agreement to modify the total cost of the Project or the Statement of Work
    and Deliverables or both within sixty (60) days, then upon the expiration of that period this Agreement shall be terminated
    and upon such termination:
	 	 	 
	 	(a)	the
    Collaborator shall pay to the NRC any costs pre-dating the effective date of the termination that were intended to be reimbursable
    to the NRC under this Agreement;
	 	 	 
	 	(a)	any
    licence or option granted under this Agreement to any Party is also terminated;
	 	 	 
	 	(b)	confidentiality
    obligations of each Party regarding the information that is part of its Arising IP are terminated except with respect to the
    Jointly Created Arising IP, both Parties continuing to be bound by all other confidentiality obligations under this Agreement.

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 5 of 14

    	 

    

 

 

	GC-6	TERMINATION
    OF AGREEMENT: This Agreement may be terminated as follows:
	 	 	 	 
	 	(a)	by
    either Party if the other Party defaults in performance of any obligation under this Agreement and fails to cure the default
    within thirty (30) days after receipt of written notice of default, and termination will take effect at the expiration of
    the cure period;
	 	 	 
	 	(b)	by
    the NRC forthwith if the Collaborator becomes bankrupt or has a receiver appointed to continue its operations, or passes a
    resolution for winding up;
	 	 	 
	 	(c)	by
    the NRC forthwith if the Collaborator has made a false or misleading representation or warranty;
	 	 	 
	 	(d)	upon
    termination:
	 	 	 	 
	 	 	(i)	the
    Collaborator shall pay to the NRC any costs pre-dating the effective date of the termination that were intended to be reimbursable
    to the NRC under this Agreement;
	 	 	 	 
	 	 	(ii)	the
    Collaborator shall also pay to the NRC any incurred costs by the NRC that result directly from the cancellation of obligations
    and from uncancellable obligations;
	 	 	 	 
	 	 	(iii)	any
    licence or option granted under this Agreement is terminated;
	 	 	 	 
	 	 	(iv)	confidentiality
    obligations of each Party regarding the information that is part of its Arising IP are terminated, both Parties continuing
    to be bound by all other confidentiality obligations under this Agreement.
	 	 	 	 
	GC-7	NOTICES:
    Any notice related to this Agreement, including a notice of change of address, must be sent to the addresses stated at
    the beginning of this Agreement, either by registered mail, which is deemed to be effective notice five days after mailing,
    or by courier or email, which are effective notices only when acknowledged by a courier’s delivery receipt or by a specific
    non-automatic return transmission.
	 	 	 	 
	GC-8	CONDITIONS:
    The Collaborator agrees that if there is any research work in the Project involving human subjects, human tissues, laboratory
    animals, or animal tissues, it shall not proceed without prior approval of the NRC’s Human Subjects Research Ethics
    Committee or Animal Care Committee and shall not be conducted in contravention of the respective Committee’s conditions
    of approval.
	 	 	 	 
	GC-9	NO
    BRIBES: The Collaborator represents and warrants to the NRC that no bribe, gift, reward, benefit or other inducement
    has been or will be paid, given, promised or offered directly or indirectly to any federal government official or employee
    or to a member of the family of such person, with a view to influencing the entry into this Agreement or the administration
    of this Agreement.
	 	 
	GC-10	NO
    DIRECT BENEFIT: The Collaborator represents and warrants to the NRC that the following individuals shall not derive
    a direct benefit from this Agreement:
	 	 	 	 
	 	(a)	a
    current or former public office holder who is not in compliance with the Conflict of Interest Act, 2006, c.9, s.2;
	 	 	 
	 	(b)	a
    current or former member of the House of Commons who is not in compliance with the Conflict of Interest Code for Members of
    the House of Commons;
	 	 	 
	 	(c)	a
    current or former public servant who is not in compliance with the Values and Ethics Code for the Public Sector; or
    
	 	 	 
	 	(d)	a
    current or former the NRC employee who is not in compliance with the NRC’s Conflict of Interest Policy.

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 6 of 14

    	 

    

 

 

	GC-11	NO
    MISREPRESENTATION: The Collaborator represents and warrants to the NRC that it, including its Directors, officers,
    employees or agents, has made no material misrepresentation, whether by omission or commission, with a view to the obtaining
    of this Agreement.
	 	 
	GC-12	NO
    CONTINGENCY FEE: The Collaborator represents and warrants to the NRC that it has not directly or indirectly paid or
    agreed to pay and that it will not directly or indirectly pay a contingency fee for the solicitation, negotiation or obtaining
    of this Agreement to any person, other than an employee acting in the normal course of the employee’s duties. In this
    section, “contingency fee” means any payment or other compensation that depends or is calculated based on the
    degree of success in soliciting, negotiating or obtaining this Agreement and “person” includes any individual
    who is required to file a return with the registrar pursuant to the Lobbying Act, R.S.C.,1985,c. 44 (4th
    Supplement) as amended. 
	 	 
	GC-13	VISITS:
    Subject to reasonable notice of the number and names and status of personnel, including employees, students and other
    persons working on behalf of the other Party and other requirements under this Agreement, a Party may, in its discretion,
    permit visits to its premises by one or more of the other Party’s personnel, if relevant to the Project and not likely
    to interfere with regular operations. 
	 	 
	GC-14	PERSONNEL:
    The Collaborator shall be liable for the actions of its personnel, including its employees, contractors, agents or students
    and shall ensure that while working on the NRC premises, they are required to comply with the following requirements:
	 	 	 	 
	 	(a)	regulations,
    policies and directives that the NRC may adopt from time to time to address access to the NRC facilities and activities thereon,
    and without limiting the generality of the foregoing, regulations, policies and directives addressing: 
	 	 	 	 
	 	 	(i)	protection
    of confidential information; 
	 	 	 	 
	 	 	(ii)	information
    management and information technology (IM/IT);
	 	 	 	 
	 	 	(iii)	harassment
    and code of conduct in the NRC facilities;
	 	 	 	 
	 	 	(iv)	protection
    of safety and health of the NRC employees, the Collaborator’s personnel and others; and
	 	 	 	 
	 	 	(v)	security
    and emergency procedures;
	 	 	 	 
	 	(b)	any
    and all security policies that the Government of Canada may promulgate from time to time including: 
	 	 	 	 
	 	 	(i)	any
    and all security conditions and requirements the NRC may request from time to time including, without limitation, undergoing
    a security screening, which may include a fingerprint check and if, following a security screening, an employee of the Collaborator
    is unable to obtain or maintain a level of security clearance that, in the sole opinion of the NRC, is adequate, such employee
    of the Collaborator will be denied access to the NRC facilities and IT Resources;
	 	 	 	 
	 	 	(ii)	the
    requirement to display an identification badge as a condition of access to the NRC facilities with or without restrictions
    on hours of access; 
	 	 	 	 
	 	 	(iii)	restrictions
    on access to the NRC’s IT Resources; the “NRC’s IT Resources” include, but are not limited to, all
    computers, telecommunications systems, workstations, PCs, laptops, storage, software, peripheral devices, servers, network
    equipment, transmission equipment, Remote Access Systems, and internal and external communications systems—such as the
    Internet, e-mail and Intranet—e-mail accounts, messages and associated files created, sent received, or stored on the
    NRC IT resources; and 
	 	 	 	 
	 	 	(iv)	the
    requirement to follow security procedures at all times and not to do anything that may compromise the integrity of the NRC
    facilities or the NRC IT Resources, with the NRC reserving the right to modify or terminate the access privileges of the Collaborator’s
    personnel at any time;
	 	 	 	 
	 	(c)	all
    confidentiality obligations under this Agreement.

 

The
NRC shall provide the Collaborator with access to all relevant legislation, regulations, policies and procedures as well as notice
of any changes, and shall provide security, health and safety training to the Collaborator’s personnel as soon as possible
following permitted access to the NRC facilities.

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 7 of 14

    	 

    

 

 

	GC-15	DISPUTE
    RESOLUTION: Disputes concerning this Agreement shall not be litigated. All disputes arising in connection with this
    Agreement which cannot be resolved through negotiations to the mutual satisfaction of both Parties within thirty (30) days,
    or such longer period as may be mutually agreed upon, may be submitted by either Party to arbitration in accordance with the
    Commercial Arbitration Act of Canada, R.S.C., 1985, c. 17 (2nd Supp.), as amended, and shall be subject to the following:
	 	 	 
	 	(a)	The
    Party requesting such arbitration shall do so by written notice to the other Party.
	 	 	 
	 	(b)	The
    arbitration shall take place in Ottawa, Ontario before a single arbitrator to be chosen jointly by the Parties. Failing agreement
    of the Parties on a single arbitrator within thirty (30) days of such notice requesting arbitration, either party may apply
    to a judge of a court having jurisdiction in Ottawa, Ontario for the appointment of a single arbitrator.
	 	 	 
	 	(c)	Each
    Party shall pay its own costs and an equal share of all of the costs of the arbitration and the fees of the arbitrator, except
    for the exceptional circumstance in which an arbitral award may require the payment of all costs by a Party who has brought
    a plainly frivolous dispute.
	 	 	 
	 	(d)	The
    arbitrator shall issue a written decision as soon as practicable after the conclusion of the final hearing, but in any event
    no later than sixty (60) days thereafter, unless that time period is extended for a fixed period by the Arbitrator on written
    notice to each Party because of illness or other cause beyond the Arbitrator’s control. The decision shall be rendered
    in such form that judgment may be entered thereon in any court having jurisdiction.
	 	 	 
	 	(e)	The
    decision shall be final and binding on the Parties in accordance with the Commercial Arbitration Act of Canada. 

 

Neither
Party may request arbitration in respect of a breach of this Agreement after the fourth anniversary of the day on which the requesting
Party first discovered that breach, unless the other Party has agreed in writing to extend the period.

 

(the
rest of this page was intentionally left blank)

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 8 of 14

    	 

    

 

 

ANNEX
IU: INTELLECTUAL PROPERTY (Uncertain)

 

	IU-1	NATURE
    OF THE PROJECT: By the nature of the Project, Arising Intellectual Property that may arise is difficult to predict,
    and the Parties consider it desirable to defer settling the terms on which it will be available until the Arising Intellectual
    Property is known.
	 	 	 
	IU-2	DEFINITIONS:
	 	 	 
	 	2.1	“Arising
    Intellectual Property” or “Arising IP” is Intellectual Property that is developed in the Project
    and that is disclosed in the Deliverables. The possessive adjective “the NRC’s” or “other Party’s”
    or “VBI’s” indicates ownership or control by that Party.
	 	 	 
	 	(a)	“Jointly
Created Arising IP” is Intellectual Property created by employees of both Parties while carrying out the Project that
is not NRC Arising IP or VBI Arising IP and shall include any Arising IP that relates to the combination of NRC-designed protein
antigens and virus like particles produced by VBI.  
	 	 	 
	 	(b)	“NRC
    Arising IP” is any Arising Intellectual Property relating specifically to assays developed solely by NRC as described
    in Task 1 of the Workplan, or relating specifically to protein antigens designed solely by NRC but it does not include Intellectual
    Property owned or controlled by VBI prior to the date of this Agreement, VBI Arising IP or the Jointly Created IP.
	 	 	 
	 	(c)	“VBI
    Arising IP” is any Arising Intellectual Property relating specifically to antigens designed solely by VBI, and to
    eVLPs and vaccines solely developed by VBI, which incorporate only those antigens solely developed by VBI, for use in the
    Project and any improvements to the Intellectual Property owned or controlled by VBI prior to date of this Agreement made
    during the course of carrying out the Project but it does not include Intellectual Property owned or controlled by NRC prior
    to the date of this Agreement, the NRC Arising IP or the Jointly Created IP.
	 	 	 
	 	2.2	“Commercially
    Exploit” is to use, reproduce and modify Arising IP, and to manufacture, use, import, and sell articles embodying
    or made by use of any Deliverables and to provide services by the use of any Deliverables.
	 	 	 
	 	2.3	“Confidential
    Non-Project Information” means any confidential or proprietary information, either of a business or technical nature,
    other than Arising Intellectual Property, disclosed by one Party to the other Party pursuant to this Agreement.
	 	 	 
	 	2.4	“Deliverables”
    are the tangible results of the Project, such as reports, physical models, samples, data records, drawings, and machine-readable
    software that are specifically mentioned in the Statement of Work and Deliverables as being deliverable. 
	 	 	 
	 	2.5	“Intellectual
    Property” or “IP” is all rights in inventions (whether patentable or not), patents, copyright
    material, trade secrets, confidential information and bacterial, viral, plant, human, or animal material that has new genetic
    or other characteristics first produced by a Party..
	 	 	 
	IU-3	ARISING
    INTELLECTUAL PROPERTY: The Parties represent that, by law or contract, they will own any Arising IP created by their
    employees. A Party who is the sole owner of Arising IP is responsible for patenting and licensing its Arising IP, but is not
    obliged by this Agreement to patent its Arising IP. VBI has the right to seek patent protection for the Jointly Created Arising
    IP at its own expense.  However, if VBI is unwilling to patent the Jointly Created Arising IP, NRC may do so at its own
    expense.  Notwithstanding the foregoing, ownership of Arising IP shall be determined as follows:
	 	 	 
	 	(a)	Any
    NRC Arising IP shall be owned by NRC, and shall be subject to the license terms described in IU-5 (a).

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 9 of 14

    	 

    

 

 

	 	(b)	Any
    VBI Arising IP shall be owned by VBI, and no license shall be granted under this Agreement except as is required to permit
    NRC to complete the Workplan. 
	 	 	 
	 	(c)	Any
    Jointly Created Arising IP shall be owned jointly by NRC and VBI, and shall be subject to the license terms described in IU-5
    (b).
	 	 	 
	 	(d)	If
    the Parties cannot come to an unanimous agreement on each Party’s contribution regarding inventorship of the Jointly
    Created Arising IP, the Parties shall both agree to refer the matter in good faith to an inventorship analysis by an independent
    unbiased third party (“Un-Biased Expert”) to provide a non-binding expert opinion to assess each researcher’s
    contribution to the invention and determine which researchers should be named as inventors on any patent applications for
    the Jointly Created Arising IP. 
	 	 	 
	IU-4	SHARING
    INFORMATION: The Parties shall keep each other promptly informed of Arising IP. Each Party shall give the other, for
    information only, a copy of any patent application for Jointly Created Arising IP immediately upon filing the application,
    and a copy of related correspondence with a patent office if requested, and the information contained in such documents and
    correspondence will be maintained in confidence until they become publicly available through no breach of this Agreement.
	 	 
	IU-5	LICENCE
    OF THE ARISING IP: Upon request by VBI no later than six (6)
    months after the end of the Project, the NRC undertakes to negotiate with VBI in good faith to settle the terms of
    a licence which will allow VBI to Commercially Exploit the NRC Arising IP and Jointly Created Arising IP on the
    following terms:
	 	 	 
	 	(a)	NRC
    Arising IP: NRC hereby grants VBI a non-exclusive option for a license to Commercially Exploit the NRC Arising
    IP, such license to include standard commercial terms to be negotiated between the Parties.
	 	 	 
	 	(b)	Jointly
    Created Arising IP: NRC hereby grants VBI an exclusive option for an exclusive license to Commercially Exploit
    the Jointly Created Arising IP, such license to include standard commercial terms to be negotiated between the Parties
	 	 	 
	 	(c)	In
    the event that VBI exercises its option pursuant to subsection (a) or (b), the Parties shall negotiate the terms of a license
    agreement in good faith for a period of three months, which period may be extended upon mutual agreement of the Parties. If
    the Parties are unable to reach an agreement on the terms of the non-exclusive license referred to in subsection (a) within
    the aforementioned period, the option shall expire and NRC shall have no further obligations with respect thereto. If
    the Parties are unable to reach an agreement on the terms of the exclusive license referred to in subsection (b), neither
    Party shall be permitted to Commercially Exploit or licence its share of the Jointly Created Arising IP without the permission
    of the other Party. Notwithstanding the foregoing, each Party shall grant to the other Party a royalty-free, exclusive
    license to use its share of the Jointly Created Arising IP solely for internal research purposes and as required to perform
    the Project and any amendments or additions thereto which are agreed upon between the Parties in writing.

 

In
addition, subject to the confidentiality provisions herein the NRC hereby licenses the other Party under Crown copyright, free
and without time limit, to use and reproduce all documents and drawings that are deliverable under this Agreement.

 

	IU-6	INTENTIONALLY
    OMITTED :
	 	 
	IU-7	NON-PROJECT
    TECHNOLOGY: If, in order to perform work in the course of the Project, a Party needs another Party’s IP that
    is not part of the Arising IP, a licence for that limited purpose is granted by this Agreement and terminates at the end of
    the Project. Any other licence must be negotiated and agreed to in writing. 

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 10 of 14

    	 

    

 

 

	IU-8	CONFIDENTIAL
    NON-PROJECT INFORMATION RESTRICTIONS: Unless otherwise stipulated in a separate agreement, the following provisions
    apply to Confidential Non-Project Information that is in electronic, written, graphic or other tangible form, including a
    physical object, that is clearly marked “Proprietary” or “Confidential” or with an equivalent legend,
    or that is oral information provided that at the time of disclosure the disclosing Party clearly identifies the confidential
    nature of such information and confirms such confidential nature by transmitting the information, in a written version that
    is marked as above, to the receiving Party within 20 days of disclosure. The receiving Party agrees not to disclose any Confidential
    Non-Project Information, including to any director, officer or employee of the receiving Party unless that individual needs
    the information to perform work in the course of the Project and is legally bound to keep confidences. In protecting Confidential
    Non-Project Information, the receiving Party must use at least the same degree of care as it uses to protect its own information
    of a similar nature, but not less than a reasonable degree of care. Unless specifically licensed, Confidential Non-Project
    Information may only be used by the receiving Party to perform work in the course of the Project. These obligations of confidentiality
    and protection will initially apply to Confidential Non-Project Information in the form of oral information but will cease
    to apply if the information is not provided in a written version within 20 days of disclosure. Notwithstanding the foregoing,
    the receiving Party may disclose the particulars of this Agreement to others of its officers and employees for internal administrative
    and business purposes, to the extent that such disclosure does not result in a public release of such information.
	 	 
	IU-9	END
    OF CONFIDENTIAL NON-PROJECT INFORMATION RESTRICTIONS: Unless otherwise stipulated in a separate agreement, all obligations
    of confidentiality and restrictions on the use of Confidential Non-Project Information in this Agreement cease to apply five
    (5) years after the expiration of this Agreement and such obligations and restrictions do not apply to information that can
    be proved to be:
	 	 	 
	 	9.1	independently
    developed by the receiving Party without reference to or use of the confidential information of the other Party;
	 	 	 
	 	9.2	received
    from a third party without breach of any obligation of confidentiality;
	 	 	 
	 	9.3	in
    the public domain at the time of its disclosure or that later enters the public domain without breach of this Agreement; or
	 	 	 
	 	9.4	required
    to be disclosed by law, including, in the case of the NRC, the Access to Information Act, provided that the receiving
    Party first provides the other Party with notice of such requirements and of its intent to disclose the information.
	 	 	 
	IU-10	CONFIDENTIALITY
    AND USE OF ARISING IP: All Deliverables and Arising IP will be maintained in confidence and protected by both Parties
    with at least the same degree of care as they use to protect their own confidential information, but not less than a reasonable
    degree of care. Arising IP shall not be disclosed except:
	 	 	 
	 	10.1	as
    required for a patent application or, where permitted by this Agreement, for a licence to a third party including disclosure
    to prospective licensees;
	 	 	 
	 	10.2	if
    the Arising IP has entered the public domain without breach of this Agreement;
	 	 	 
	 	10.3	as
    required to be disclosed by law, including, in the case of the NRC, the Access Information Act, provided that the receiving
    Party first provides the other Party with notice of such requirements and of its intent to disclose information; 
	 	 	 
	 	10.4	NRC
    may disclose the NRC Arising IP and VBI may disclose the VBI Arising IP to the extent that such disclosure does not lead to
    disclosure of the Jointly Created Arising IP; or 
	 	 	 
	 	10.5	As
    is permitted by Section IU-12 or as otherwise agreed to by the Parties.

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 11 of 14

    	 

    

 

 

	IU-11	PUBLICITY:
    No Party will publicly suggest that the other Party endorses or recommends any product or process or results of the
    Project.
	 	 
	IU-12	PUBLICATION:
    The Parties may jointly publish, or jointly agree in writing to allow one Party to publish, Confidential Information arising
    from the Project. If a Party requests in writing permission to publish and the other Party does not respond within
    thirty (30) days, permission is assumed. Such publications must fairly assign credit to the individual researchers
    involved. Any publication can be delayed by a period reasonable to allow the Parties to file for intellectual
    property protection. If a license is granted by NRC to VBI for the Jointly Created IP, VBI shall be expressly permitted
    to publish information regarding the Jointly Created IP without further permission.  
	 	 
	IU-13	PRESS
    RELEASE: The Parties hereby acknowledge that VBI is a publicly traded entity and subject to Securities
    and Exchange Commission regulation on disclosure within five (5) days of execution without disclosing any confidential information
    protected under this Agreement. VBI will draft a press release for the NRC’s contributions, review and approval
    within a timely manner, which approval will not be unreasonably withheld and will be assumed if no response if received within
    four (4) business days of receipt.  
	 	 
	IU-14	NO
    IMPLIED WARRANTIES: The NRC’s Arising IP is supplied and licensed on a “as is” basis, and there
    are no representations, warranties or conditions, express or implied by statute, including without limitation any with respect
    to:
	 	 	 	 
	 	14.1	market
    readiness, merchantability, or fitness for any use or purpose;
	 	 	 
	 	14.2	operational
    state, character, quality, or freedom from defects;
	 	 	 
	 	14.3	validity
    of patents;
	 	 	 
	 	14.4	non-infringement
    of rights of third parties under present or future patents.
	 	 	 	 
	IU-15	NO
    CONTESTATION OF VALIDITY: The Parties acknowledge the validity of the patents and copyright, if any licensed hereunder
    and agrees not to contest such validity, either directly or indirectly by assisting other parties.
	 	 
	IU-16	INDEMNITY:
    The NRC rejects all liability and responsibility relating to the consequences of using the NRC’s Arising IP. The
    other Party shall indemnify and save harmless the NRC, its employees and agents from and against, and be responsible for:
	 	 	 	 
	 	16.1	all
    claims, demands, losses, damages, costs including solicitor and client costs, actions, suits or proceedings brought by any
    third party, that are in any manner based upon, arising out of, related to, occasioned by, or attributable to: 
	 	 	 	 
	 	 	(a)	the
    use by the other Party of the NRC’s Arising IP including without limitation, the manufacturing, distribution, shipment,
    offering for sale, sale, or use of products and services derived from the NRC’s Arising IP; and 
	 	 	 	 
	 	 	(b)	product
    liability and infringement of Intellectual Property rights other than copyright, if any, licensed hereunder; 
	 	 	 	 
	 	16.2	other
    costs, including extra-judicial costs, of the NRC defending such any action or proceeding, which the NRC shall have the right
    to defend with counsel of its choice.

 

This
clause shall survive expiration or termination of this Agreement.

 

(the
rest of this page was intentionally left blank)

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 12 of 14

    	 

    

 

 

STATEMENT
OF WORK AND DELIVERABLES

 

Multivalent
Coronavirus vaccine development

 

VBI
and the NRC are proposing a collaborative effort to develop a multivalent Coronavirus vaccine (with the goal to cross-protect
against known strains of SARS-2, SARS & MERS) which would have utility against current known and potential new strains of
Coronavirus. 

 

VBI
has initiated work to design monovalent & multivalent coronavirus constructs using their eVLP platform and will include 3-4
protein antigens provided by NRC.

 

Phase
1 Objective: To establish the potency of VBI monovalent and multivalent Coronavirus eVLP vaccine preparations

 

Task
1: Assay Development – NRC ($[***] co-investment) 

 

SARS-CoV-2
requires novel assays to evaluate immunogenicity. NRC is developing [***]. Depending on the time to development, [***]will
be used to evaluate the immunogenicity of the vaccine candidates. The [***]assays to be developed are a PRNT assay [***]
(using pseudovirus).

Task
2: Preclinical Potency Testing (per construct) – Price: $[***] (Task value: $[***])

 

Group
assignments (n=[***]**):

 

	 	1)	[***]
	 	2)	[***]vaccine*
	 	3)	[***]vaccine*
	 	4)	[***]vaccine*
	 	5)	[***]
    vaccine*

 

*dose
and [***]vs [***]to be determined by VBI 

 

**choice
of [***]to be discussed with VBI

 

Mice
will be [***]. Blood will be sampled [***]after each immunization to conduct immunogenicity assays ([***]
at VBI and [***]at NRC). [***]will only be done on serum samples [***].

 

Future
Anticipated Work: It is anticipated that additional animal studies can be added as separate experiments as required. VBI
anticipates developing [***] but these will be tested at a later date. VBI also remains open to testing [***]designs
as [***]are available for coding in eVLP.

Task
3: PRNT Assay (per iteration of Task 1) – Price $[***] (Task value: $[***])

Task
4: Reporter assay using pseudovirus (per iteration of Task 1) – Price $[***] (Task value: $[***])

Total
Estimated Budget (first iteration of Tasks 2-4): $[***]

 

	Budget
    Summary: VBI Multivalent eVLP vaccine candidate against coronaviruses
	Work
    Task	 	Task
    Value 	 	NRC
Co-investment 	 	CAN
    SME Fee Reduction 	 	NRC
    Task Price* 
	Task
    1: Assay development	 	[***]	 	[***]	 	 	 	 
	Task
    2: Immunogenicity in vivo	 	[***]	 	 	 	[***]	 	[***]
	Task
    3: PRNT assay	 	[***]	 	 	 	[***]	 	[***]
	Task
    4: Reporter assay	 	[***]	 	 	 	[***]	 	[***]
	Total
    Minimum (without options)*	 	[***]	 	 [***]	 	[***]	 	[***]
	Total
    Maximum (with options)*	 	[***]	 	 [***]	 	 [***]	 	[***]
	*
    Plus applicable taxes	 	 	 	 	 	 	 	 

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 13 of 14

    	 

    

 

 

OPTION:
VBI may wish to exercise the option to execute another iteration of Tasks 1-3. This option is [***] in total ($[***]).

 

Assumptions:

 

	 	1)	Availability
    of sufficient material from VBI and suppliers to conduct experiments.
	 	2)	Resource
    availability
	 	3)	Relevant
    PRNT and reporter assays are established in-house. 

 

Deliverables

 

	 	●	Experimental
    protocols and results, including raw data in Microsoft Office file format.
	 	●	A
    summary report for each study.

 

Contacts:

 

For
the NRC:

 

Paul
Payette, Ph.D., MBA, Client Relationship Leader

Email:
[***]

 

Anh
Tran, Ph.D., Assistant Research Officer - HHT

Email:
[***]

 

Rhonda
Kuo Lee, Project Manager, HHT

Email:
[***]

 

For
the Collaborator:

 

Adam
Buckley, VP – Business Development

Email:
[***]

 

    	Human Health Therapeutics – Vaccines and Emerging Infections RI
NRC Internal Use: A-0035546
	Page 14 of 14

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]